# EDGAR Filing Document

**Accession Number:** 0000010456
**File Stem:** 0001628280-26-028962
**Filing Date:** 2026-4
**Character Count:** 173615
**Document Hash:** 52c11b059176a076ff682084f666bd85
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-028962.hdr.sgml**: 20260430

**ACCESSION NUMBER**: 0001628280-26-028962

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 95

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260430

**DATE AS OF CHANGE**: 20260430

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BAXTER INTERNATIONAL INC
- **CENTRAL INDEX KEY:** 0000010456
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 360781620
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-04448
- **FILM NUMBER:** 26926607

**BUSINESS ADDRESS:**
- **STREET 1:** ONE BAXTER PARKWAY
- **CITY:** DEERFIELD
- **STATE:** IL
- **ZIP:** 60015
- **BUSINESS PHONE:** 2249482000

**MAIL ADDRESS:**
- **STREET 1:** ONE BAXTER PARKWAY
- **CITY:** DEERFIELD
- **STATE:** IL
- **ZIP:** 60015

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BAXTER TRAVENOL LABORATORIES INC
- **DATE OF NAME CHANGE:** 19880522

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BAXTER LABORATORIES INC
- **DATE OF NAME CHANGE:** 19760608

?xml version='1.0' encoding='ASCII'? bax-20260331

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**_________________________________________________________________________________**

**FORM 10-Q**

**_________________________________________________________________________________**

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended March 31, 2026** 

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**

**Commission file number 1-4448**

**_________________________________________________________________________________**

**BAXTER INTERNATIONAL INC.**

**(Exact name of registrant as specified in its charter)**

**_________________________________________________________________________________**

---

| | | | |
|:---|:---|:---|:---|
| **Delaware** | **Delaware** | **Delaware** | 36-0781620 |
| (State or other jurisdiction of<br>incorporation or organization) | (State or other jurisdiction of<br>incorporation or organization) | (State or other jurisdiction of<br>incorporation or organization) | (I.R.S. Employer<br>Identification No.) |
| **One Baxter Parkway,** | **Deerfield,** | **Illinois** | 60015 |
| **(Address of Principal Executive Offices)** | **(Address of Principal Executive Offices)** | **(Address of Principal Executive Offices)** | (Zip Code) |

---

 224. 948.2000 <br> (Registrant's telephone number, including area code)

**_________________________________________________________________________________**

<u>Securities registered pursuant to Section 12(b) of the Act:</u>

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, $1.00 par value | BAX (NYSE) | New York Stock Exchange |
| 1.3% Global Notes due 2029 | BAX 29 | New York Stock Exchange |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ⌧ No □

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ⌧ No □

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ⌧ | Accelerated filer | □ |
| Non-accelerated filer | □ | Smaller reporting company | ☐ |
| Emerging growth company | ☐ | | |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp;&nbsp;&nbsp;□

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). &nbsp;&nbsp;&nbsp;&nbsp;Yes ☐ No ⌧

The number of shares of the registrant's Common Stock, par value $1.00 per share, outstanding as of April 24, 2026 was 516,469,008 shares.

------

BAXTER INTERNATIONAL INC.

FORM 10-Q

For the quarterly period ended March 31, 2026

**TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
| | | Page Number |
| <u>[PART I.](#i01c676f6e92d4d01a169dc8d9efa8cc9_10)</u> | <u>[FINANCIAL INFORMATION](#i01c676f6e92d4d01a169dc8d9efa8cc9_10)</u> | [2](#i01c676f6e92d4d01a169dc8d9efa8cc9_10) |
| [Item 1.](#i01c676f6e92d4d01a169dc8d9efa8cc9_13) | <u>[Financial Statements (unaudited)](#i01c676f6e92d4d01a169dc8d9efa8cc9_13)</u> | [2](#i01c676f6e92d4d01a169dc8d9efa8cc9_13) |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Balance Sheets](#i01c676f6e92d4d01a169dc8d9efa8cc9_16)</u> | [2](#i01c676f6e92d4d01a169dc8d9efa8cc9_16) |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statements of Income (Loss)](#i01c676f6e92d4d01a169dc8d9efa8cc9_19)</u> | [3](#i01c676f6e92d4d01a169dc8d9efa8cc9_19) |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statements of Comprehensive Income (Loss)](#i01c676f6e92d4d01a169dc8d9efa8cc9_22)</u> | [4](#i01c676f6e92d4d01a169dc8d9efa8cc9_22) |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statements of Changes in Equity](#i01c676f6e92d4d01a169dc8d9efa8cc9_25)</u> | [5](#i01c676f6e92d4d01a169dc8d9efa8cc9_25) |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statements of Cash Flows](#i01c676f6e92d4d01a169dc8d9efa8cc9_28)</u> | [6](#i01c676f6e92d4d01a169dc8d9efa8cc9_28) |
|  | <u>[Notes to Condensed Consolidated Financial Statements](#i01c676f6e92d4d01a169dc8d9efa8cc9_31)</u> | [7](#i01c676f6e92d4d01a169dc8d9efa8cc9_31) |
| [Item 2.](#i01c676f6e92d4d01a169dc8d9efa8cc9_88) | <u>[Management's Discussion and Analysis of Financial Condition and Results of Operations](#i01c676f6e92d4d01a169dc8d9efa8cc9_88)</u> | [29](#i01c676f6e92d4d01a169dc8d9efa8cc9_88) |
| [Item 3.](#i01c676f6e92d4d01a169dc8d9efa8cc9_139) | <u>[Quantitative and Qualitative Disclosures about Market Risk](#i01c676f6e92d4d01a169dc8d9efa8cc9_139)</u> | [44](#i01c676f6e92d4d01a169dc8d9efa8cc9_139) |
| [Item 4.](#i01c676f6e92d4d01a169dc8d9efa8cc9_142) | <u>[Controls and Procedures](#i01c676f6e92d4d01a169dc8d9efa8cc9_142)</u> | [45](#i01c676f6e92d4d01a169dc8d9efa8cc9_142) |
| <u>[PART II.](#i01c676f6e92d4d01a169dc8d9efa8cc9_145)</u> | <u>[OTHER INFORMATION](#i01c676f6e92d4d01a169dc8d9efa8cc9_145)</u> | [46](#i01c676f6e92d4d01a169dc8d9efa8cc9_145) |
| [Item 1.](#i01c676f6e92d4d01a169dc8d9efa8cc9_148) | <u>[Legal Proceedings](#i01c676f6e92d4d01a169dc8d9efa8cc9_148)</u> | [46](#i01c676f6e92d4d01a169dc8d9efa8cc9_148) |
| Item 1A. | <u>[Risk Factors](#i01c676f6e92d4d01a169dc8d9efa8cc9_151)</u> | [46](#i01c676f6e92d4d01a169dc8d9efa8cc9_148) |
| [Item 2.](#i01c676f6e92d4d01a169dc8d9efa8cc9_154) | <u>[Unregistered Sales of Equity Securities and Use of Proceeds](#i01c676f6e92d4d01a169dc8d9efa8cc9_154)</u> | [46](#i01c676f6e92d4d01a169dc8d9efa8cc9_154) |
| Item 5. | <u>[Other Information](#i01c676f6e92d4d01a169dc8d9efa8cc9_157)</u> | [46](#i01c676f6e92d4d01a169dc8d9efa8cc9_157) |
| [Item 6.](#i01c676f6e92d4d01a169dc8d9efa8cc9_163) | <u>[Exhibits](#i01c676f6e92d4d01a169dc8d9efa8cc9_163)</u> | [47](#i01c676f6e92d4d01a169dc8d9efa8cc9_163) |
| <u>[Signature](#i01c676f6e92d4d01a169dc8d9efa8cc9_166)</u> |  | [48](#i01c676f6e92d4d01a169dc8d9efa8cc9_166) |

---

------

PART I. FINANCIAL INFORMATION

Item 1.&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements

Baxter International Inc.

Condensed Consolidated Balance Sheets (unaudited)

(in millions, except share information)

---

| | | |
|:---|:---|:---|
| | March 31,<br>2026 | December 31,<br>2025 |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $2017 | 1966 |
| &nbsp;&nbsp;Accounts receivable, net of allowances of $67 in 2026 and $63 in 2025 | 1698 | 1861 |
| &nbsp;&nbsp;&nbsp;Inventories | 2316 | 2232 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 816 | 813 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 6847 | 6872 |
| Property, plant and equipment, net | 2913 | 2910 |
| Goodwill | 4899 | 4929 |
| Other intangible assets, net | 4218 | 4369 |
| Operating lease right-of-use assets | 277 | 276 |
| Other non-current assets | 692 | 699 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total assets | $19846 | $20055 |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;Short-term debt | $— | $1 |
| &nbsp;&nbsp;&nbsp;Current maturities of long-term debt and finance lease obligations | 842 | 2 |
| &nbsp;&nbsp;&nbsp;Accounts payable | 1086 | 999 |
| &nbsp;&nbsp;&nbsp;Accrued expenses and other current liabilities | 1765 | 1968 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 3693 | 2970 |
| Long-term debt and finance lease obligations, less current portion | 8621 | 9473 |
| Operating lease liabilities | 224 | 223 |
| Other non-current liabilities | 1292 | 1287 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 13830 | 13953 |
| Commitments and contingencies |  |  |
| Equity: |  |  |
| Common stock, $1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares in 2026 and 2025 | 683 | 683 |
| Common stock in treasury, at cost, 167,047,900 shares in 2026 and 169,213,617 shares in 2025 | (10737) | (10873) |
| Additional contributed capital | 6214 | 6368 |
| Retained earnings | 13685 | 13705 |
| Accumulated other comprehensive loss | (3802) | (3754) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Baxter stockholders' equity | 6043 | 6129 |
| &nbsp;&nbsp;&nbsp;Noncontrolling interests | (27) | (27) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total equity | 6016 | 6102 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and equity | $19846 | $20055 |

---

The accompanying notes are an integral part of these condensed consolidated financial statements.

------

Baxter International Inc.

Condensed Consolidated Statements of Income (Loss) (unaudited)

(in millions, except per share data)

---

| | | |
|:---|:---|:---|
| | Three months ended<br>March 31, | Three months ended<br>March 31, |
| | 2026 | 2025 |
| Net sales | $2701 | $2625 |
| Cost of sales | 1810 | 1764 |
| Gross margin | 891 | 861 |
| Selling, general and administrative expenses | 728 | 703 |
| Research and development expenses | 139 | 140 |
| Other operating income, net | (42) | (40) |
| Operating income | 66 | 58 |
| Interest expense, net | 66 | 64 |
| Other (income) expense, net | 6 | (3) |
| Income (loss) from continuing operations before income taxes | (6) | (3) |
| Income tax expense (benefit) | 11 | (67) |
| Income (loss) from continuing operations | (17) | 64 |
| Income (loss) from discontinued operations, net of tax | 2 | 62 |
| Net income (loss) | (15) | 126 |
| Net income attributable to noncontrolling interests |  |  |
| Net income (loss) attributable to Baxter stockholders | $(15) | $126 |
| **Income (loss) from continuing operations per common share** | **Income (loss) from continuing operations per common share** | **Income (loss) from continuing operations per common share** |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | $(0.03) | $0.13 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | $(0.03) | $0.13 |
| **Income (loss) from discontinued operations per common share** | **Income (loss) from discontinued operations per common share** | **Income (loss) from discontinued operations per common share** |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | $— | $0.12 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | $— | $0.12 |
| **Income (loss) per common share** | **Income (loss) per common share** | **Income (loss) per common share** |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | $(0.03) | $0.25 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | $(0.03) | $0.25 |
| **Weighted-average number of shares outstanding** | **Weighted-average number of shares outstanding** | **Weighted-average number of shares outstanding** |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | 515 | 512 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | 515 | 514 |

---

The accompanying notes are an integral part of these condensed consolidated financial statements.

------

Baxter International Inc.

Condensed Consolidated Statements of Comprehensive Income (Loss) (unaudited)

(in millions)

---

| | | |
|:---|:---|:---|
| | Three months ended<br>March 31, | Three months ended<br>March 31, |
| | 2026 | 2025 |
| Income (loss) from continuing operations | $(17) | $64 |
| Other comprehensive income (loss) from continuing operations, net of tax: |  |  |
| Currency translation adjustments, net of tax expense (benefit) of $15 and $6 for the three months ended March 31, 2026 and 2025, respectively. | (52) | (68) |
| Pension and other postretirement benefits, net of tax expense (benefit) of $1 and $(4) for the three months ended March 31, 2026 and 2025, respectively. | 3 | 12 |
| Hedging activities, net of tax expense (benefit) of zero and $(1) for the three months ended March 31, 2026 and 2025, respectively. | 1 | (2) |
| Total other comprehensive income (loss) from continuing operations, net of tax | (48) | (58) |
| Comprehensive income (loss) from continuing operations | (65) | 6 |
| Income (loss) from discontinued operations, net of tax | 2 | 62 |
| Other comprehensive income (loss) from discontinued operations |  |  |
| Currency translation adjustments, net of tax expense (benefit) of zero for the three months ended March 31, 2026 and 2025, respectively. |  | 137 |
| Pension and other postretirement benefits, net of tax expense (benefit) of zero and $(3) for the three months ended March 31, 2026 and 2025, respectively.  |  | (11) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total other comprehensive income (loss) from discontinued operations |  | 126 |
| &nbsp;&nbsp;&nbsp;&nbsp;Comprehensive income (loss) from discontinued operations | 2 | 188 |
| Comprehensive income (loss) | (63) | 194 |
| Less: Comprehensive income attributable to noncontrolling interests |  |  |
| Less: Other comprehensive loss attributable to noncontrolling interests |  |  |
| Comprehensive income (loss) attributable to Baxter stockholders | $(63) | $194 |

---

The accompanying notes are an integral part of these condensed consolidated financial statements.

------

Baxter International Inc.

Condensed Consolidated Statements of Changes in Equity (unaudited)

(in millions)

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | For the three months ended March 31, 2026 | For the three months ended March 31, 2026 | For the three months ended March 31, 2026 | For the three months ended March 31, 2026 | For the three months ended March 31, 2026 | For the three months ended March 31, 2026 | For the three months ended March 31, 2026 | For the three months ended March 31, 2026 | For the three months ended March 31, 2026 | For the three months ended March 31, 2026 |
| | Baxter International Inc. stockholders' equity | Baxter International Inc. stockholders' equity | Baxter International Inc. stockholders' equity | Baxter International Inc. stockholders' equity | Baxter International Inc. stockholders' equity | Baxter International Inc. stockholders' equity | Baxter International Inc. stockholders' equity | Baxter International Inc. stockholders' equity | | |
| | Common stock shares | Common stock | Common stock shares<br>in treasury | Common stock in<br>treasury | Additional contributed capital | Retained earnings | Accumulated other comprehensive<br>income (loss) | Total Baxter stockholders' equity |<br>Noncontrolling interests |<br>Total equity |
| Balance as of January 1, 2026 | 683 | $683 | 169 | $(10873) | $6368 | $13705 | $(3754) | $6129 | $(27) | $6102 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) |  |  |  |  |  | (15) |  | (15) |  | (15) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income (loss) |  |  |  |  |  |  | (48) | (48) |  | (48) |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock issued under employee benefit plans and other |  |  | (2) | 136 | (154) |  |  | (18) |  | (18) |
| &nbsp;&nbsp;&nbsp;&nbsp;Dividends declared on common stock |  |  |  |  |  | (5) |  | (5) |  | (5) |
| Balance as of March 31, 2026 | 683 | $683 | 167 | $(10737) | $6214 | $13685 | $(3802) | $6043 | $(27) | $6016 |

---

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | For the three months ended March 31, 2025 | For the three months ended March 31, 2025 | For the three months ended March 31, 2025 | For the three months ended March 31, 2025 | For the three months ended March 31, 2025 | For the three months ended March 31, 2025 | For the three months ended March 31, 2025 | For the three months ended March 31, 2025 | For the three months ended March 31, 2025 | For the three months ended March 31, 2025 |
| | Baxter International Inc. stockholders' equity | Baxter International Inc. stockholders' equity | Baxter International Inc. stockholders' equity | Baxter International Inc. stockholders' equity | Baxter International Inc. stockholders' equity | Baxter International Inc. stockholders' equity | Baxter International Inc. stockholders' equity | Baxter International Inc. stockholders' equity | | |
| | Common stock shares | Common stock | Common stock shares in treasury | Common stock in treasury | Additional contributed capital | Retained earnings | Accumulated other comprehensive income (loss) | Total Baxter stockholders' equity |<br>Noncontrolling interests |<br>Total equity |
| Balance as of January 1, 2025 | 683 | $683 | 173 | $(11059) | $6421 | $14929 | $(4010) | $6964 | $60 | $7024 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) |  |  |  |  |  | 126 |  | 126 |  | 126 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income (loss) |  |  |  |  |  |  | (47) | (47) |  | (47) |
| &nbsp;&nbsp;&nbsp;&nbsp;Reclassification of other comprehensive income (loss) disposed in the Kidney Care separation |  |  |  |  |  |  | 115 | 115 |  | 115 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock issued under employee benefit plans and other |  |  | (3) | 122 | (112) |  |  | 10 |  | 10 |
| &nbsp;&nbsp;&nbsp;&nbsp;Dividends declared on common stock |  |  |  |  |  | (87) |  | (87) |  | (87) |
| &nbsp;&nbsp;&nbsp;&nbsp;Disposition of noncontrolling interest associated with the Kidney Care separation |  |  |  |  |  |  |  |  | (87) | (87) |
| Balance as of March 31, 2025 | 683 | $683 | 170 | $(10937) | $6309 | $14968 | $(3942) | $7081 | $(27) | $7054 |

---

The accompanying notes are an integral part of these condensed consolidated financial statements.

------

Baxter International Inc.

Condensed Consolidated Statements of Cash Flows (unaudited)

(in millions)

---

| | | |
|:---|:---|:---|
| | Three Months Ended March 31, | Three Months Ended March 31, |
| | 2026 | 2025 |
| Cash flows from operations |  |  |
| &nbsp;&nbsp;&nbsp;Net income (loss) | $(15) | $126 |
| &nbsp;&nbsp;&nbsp;Less: Income (loss) from discontinued operations, net of tax | 2 | 62 |
| &nbsp;&nbsp;&nbsp;Income (loss) from continuing operations | (17) | 64 |
| &nbsp;&nbsp;&nbsp;Adjustments to reconcile net income (loss) to cash flows from operations: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 237 | 247 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes | 29 | (142) |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock compensation | 10 | 10 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net periodic pension and other postretirement costs | (4) | (8) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other long-lived asset impairments |  | 22 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | 13 | 6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Changes in balance sheet items: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net | 152 | 26 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories | (95) | (122) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 2 | (24) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | 102 | 16 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses and other current liabilities | (203) | (143) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | (13) | (51) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash flows from (used in) operations - continuing operations | 213 | (99) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash flows from (used in) operations - discontinued operations |  | (94) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash flows from (used in) operations | 213 | (193) |
| Cash flows from investing activities |  |  |
| &nbsp;&nbsp;&nbsp;Capital expenditures | (137) | (122) |
| &nbsp;&nbsp;&nbsp;Other investing activities, net | 4 | (2) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash flows from (used in) investing activities - continuing operations | (133) | (124) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash flows from (used in) investing activities - discontinued operations |  | 3389 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash flows from (used in) investing activities | (133) | 3265 |
| Cash flows from financing activities |  |  |
| &nbsp;&nbsp;&nbsp;Repayments of debt |  | (2825) |
| &nbsp;&nbsp;&nbsp;Repayments of debt with original maturities of three months or less |  | (300) |
| &nbsp;&nbsp;&nbsp;Cash dividends on common stock | (5) | (87) |
| &nbsp;&nbsp;&nbsp;Proceeds from stock issued under employee benefit plans | 8 | 10 |
| &nbsp;&nbsp;&nbsp;Other financing activities, net | (14) | (24) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash flows from (used in) financing activities | (11) | (3226) |
| Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash - continuing operations | (18) | 36 |
| Increase (decrease) in cash, cash equivalents and restricted cash | 51 | (118) |
| Cash, cash equivalents and restricted cash at beginning of period <sup>(1)</sup> | 1968 | 2414 |
| Cash, cash equivalents and restricted cash at end of period <sup>(1)</sup> | 2019 | 2296 |
| Less cash and cash equivalents of discontinued operations |  |  |
| Cash, cash equivalents and restricted cash of continuing operations | $2019 | $2296 |

---

(1) The following table provides a reconciliation of cash, cash equivalents and restricted cash shown above to the amounts reported within the condensed consolidated balance sheet as of March 31, 2026, December 31, 2025, and March 31, 2025 (in millions):

---

| | | | |
|:---|:---|:---|:---|
| | March 31, 2026 | December 31, 2025 | March 31, 2025 |
| Cash and cash equivalents | $2017 | $1966 | $2294 |
| Restricted cash included in other non-current assets | 2 | 2 | 2 |
| Cash, cash equivalents and restricted cash | $2019 | $1968 | $2296 |

---

The accompanying notes are an integral part of these condensed consolidated financial statements.

------

Baxter International Inc.

Notes to Condensed Consolidated Financial Statements (unaudited)

**<u>1. BASIS OF PRESENTATION</u>**

The unaudited interim condensed consolidated financial statements of Baxter International Inc. and its subsidiaries (we, our or Baxter) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) for interim financial reporting. Accordingly, certain information and note disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) in the United States have been condensed or omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2025 (2025 Annual Report).

In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. All such adjustments, unless otherwise noted herein, are of a normal, recurring nature. The disclosures presented in our notes to the consolidated financial statements are presented on a continuing operations basis. The results of operations for the current interim period are not necessarily indicative of the results of operations to be expected for the full year.

**<u>2. DISCONTINUED OPERATIONS</u>**

A component of an entity is reported in discontinued operations after meeting the criteria for held-for-sale classification if the disposition represents a strategic shift that has (or will have) a major effect on the entity's operations and financial results. The condensed consolidated financial statements reflect discontinued operations presentation as described below.

**Discontinued Operations - Kidney Care**

On January 31, 2025, we completed the sale of our Kidney Care business to certain affiliates of Carlyle Group Inc. (Carlyle). That business, which is known as Vantive Health LLC (Vantive) is comprised of our former Kidney Care segment and provides chronic and acute dialysis therapies and services, including peritoneal dialysis, hemodialysis, continuous renal replacement therapies, and other organ support therapies.

Upon closing of the sale of the Kidney Care business, pursuant to the Equity Purchase Agreement (EPA), Baxter and Vantive entered into several agreements, including a Manufacturing and Supply Agreement (Kidney Care MSA), a Transition Services Agreement (Kidney Care TSA), a Long Term Master Services Agreement, a Distribution Agreement and certain other arrangements providing for short-term supply of saline products, and an Intellectual Property Agreement. Pursuant to the Kidney Care MSA, Baxter and the Kidney Care divested entities provide each other with certain dialysis-related products, other products, product components and fulfillment services for up to 10 years post-closing (with certain extension rights and early exit rights as provided therein). Pursuant to the Kidney Care MSA, our sales to Vantive are recognized in net sales in the condensed consolidated statements of income (loss). Pursuant to the Kidney Care TSA, Baxter and the entities that were divested in connection with the Kidney Care sale (the Kidney Care divested entities) provide each other, on an interim basis, certain transitional services for up to 30 months post-closing (with certain extension rights and early exit rights as provided therein) to help ensure business continuity and help minimize disruptions to the operations of both parties post-closing. Services provided under the Kidney Care TSA include information technology applications and support, supply chain and certain other corporate and administrative services. Billings by us under the Kidney Care TSA are recorded in other operating income, net in the condensed consolidated statements of income (loss). The costs to provide each respective service is recorded in the applicable expense category in the condensed consolidated statements of income (loss).

In accordance with the EPA, we have agreed to indemnify Vantive for certain items, including taxes imposed on or with respect to the Kidney Care divested entities, for pre-closing tax periods. The net indemnification liability as of March 31, 2026 was $53 million. Further, in accordance with the EPA, Baxter recorded a contingent liability for payments to reimburse Vantive for qualifying capital expenditures of $133 million over a period of three years post sale. The contingent liability as of March 31, 2026 was $83 million based on payments made to date.

Certain of the business guarantees originally entered by us on behalf of the Kidney Care business were not released prior to the completion of the sale and remain outstanding. These legacy guarantees primarily relate to certain leases, performance contracts and ones to support regulatory requirements of the Kidney Care business. As of March 31,

------

2026, the total amount of Kidney Care business guarantees retained by us was approximately $24 million. Under terms of the EPA, Carlyle has agreed to indemnify us for any cost or expense, or payments made in the future under these arrangements.

**Results of Discontinued Operations**

The following tables summarize the major classes of line items included in income (loss) from discontinued operations, net of tax, for the three months ended March 31, 2025:

---

| | |
|:---|:---|
| | Three Months Ended March 31, |
| (in millions) | 2025 |
| Net sales | $352 |
| Cost of sales | 206 |
| Gross margin | 146 |
| Selling, general and administrative expenses | 116 |
| Research and development expenses | 16 |
| Goodwill impairment |  |
| Other operating income, net |  |
| Operating income (loss) | 14 |
| Interest expense, net | 13 |
| Other (income) expense, net | 7 |
| Income (loss) from discontinued operations before gain on disposition and income taxes | (6) |
| Gain (loss) on disposition | 191 |
| Income tax expense (benefit) | 123 |
| Income (loss) from discontinued operations, net of tax | 62 |
| Less: Net income attributable to noncontrolling interest included in discontinued operations |  |
| Net income (loss) attributable to Baxter stockholders included in discontinued operations | $62 |

---

**<u>3. SUPPLEMENTAL FINANCIAL INFORMATION</u>**

**Allowance for Doubtful Accounts**

The following table is a summary of the changes in our allowance for doubtful accounts for the three months ended March 31, 2026 and 2025.

---

| | | |
|:---|:---|:---|
| | Three Months Ended March 31, | Three Months Ended March 31, |
| (in millions) | 2026 | 2025 |
| Balance at beginning of period | $63 | $71 |
| Charged to costs and expenses | 5 | (4) |
| Write-offs | (1) | (2) |
| Currency translation adjustments |  | 1 |
| Balance at end of period | $67 | $66 |

---

------

**Inventories** 

---

| | | |
|:---|:---|:---|
| (in millions) | March 31,<br>2026 | December 31,<br>2025 |
| Raw materials | $567 | $536 |
| Work in process | 390 | 369 |
| Finished goods | 1359 | 1327 |
| Inventories | $2316 | $2232 |

---

**Property, Plant and Equipment, Net** 

---

| | | |
|:---|:---|:---|
| (in millions) | March 31,<br>2026 | December 31,<br>2025 |
| Property, plant and equipment, at cost | $8099 | $8054 |
| Accumulated depreciation | (5186) | (5144) |
| Property, plant and equipment, net | $2913 | $2910 |

---

**Interest Expense, Net**

---

| | | |
|:---|:---|:---|
| | Three Months Ended March 31, | Three Months Ended March 31, |
| (in millions) | 2026 | 2025 |
| Interest expense, net of capitalized interest | $78 | $81 |
| Interest income | (12) | (17) |
| Interest expense, net | $66 | $64 |

---

**Other (Income) Expense, Net**

---

| | | |
|:---|:---|:---|
| | Three Months Ended March 31, | Three Months Ended March 31, |
| (in millions) | 2026 | 2025 |
| Foreign exchange losses, net | $3 | $— |
| Pension and other postretirement benefit plans | (7) | (11) |
| Change in fair value of marketable equity securities | 4 | 1 |
| Investment impairments | 5 | 9 |
| Other, net | 1 | (2) |
| Other (income) expense, net | $6 | $(3) |

---

**Non-Cash Operating and Investing Activities**

Right-of-use operating lease assets obtained in exchange for lease obligations for the three months ended March 31, 2026 and 2025 were $20 million and $5 million, respectively.

Purchases of property, plant and equipment included in accounts payable as of March 31, 2026 and 2025 were $54 million and $39 million, respectively.

------

**<u>4. GOODWILL AND OTHER INTANGIBLE ASSETS, NET</u>**

**Goodwill**

The following is a reconciliation of goodwill by segment.

---

| | | | | |
|:---|:---|:---|:---|:---|
| (in millions) | Medical Products & Therapies | Healthcare Systems & Technologies | Pharmaceuticals | Total |
| Balance as of December 31, 2025 | $1265 | $3087 | $577 | $4929 |
| Currency translation | (17) | (5) | (8) | (30) |
| Balance as of March 31, 2026 | $1248 | $3082 | $569 | $4899 |

---

**Other intangible assets, net**

The following is a summary of our other intangible assets.

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | | | | | Indefinite-lived intangible assets | Indefinite-lived intangible assets | |
| (in millions) | Customer relationships | Developed technology, including patents | Trade names | Other amortized intangible assets | Trade names | In process Research and Development | <br>Total |
| <u>December 31, 2025</u> |  |  |  |  |  |  |  |
| Gross other intangible assets | $3393 | $3208 | $953 | $91 | $390 | $107 | $8142 |
| Accumulated amortization | (1095) | (2434) | (172) | (72) |  |  | (3773) |
| Other intangible assets, net | $2298 | 774 | 781 | 19 | 390 | 107 | 4369 |
| <u>March 31, 2026</u> |  |  |  |  |  |  |  |
| Gross other intangible assets | $3392 | $3194 | $953 | $90 | $390 | $107 | $8126 |
| Accumulated amortization | (1148) | (2498) | (190) | (72) |  |  | (3908) |
| Other intangible assets, net | $2244 | $696 | $763 | $18 | $390 | $107 | $4218 |

---

Intangible asset amortization expense was $146 million and $155 million for the three months ended March 31, 2026 and 2025, respectively.

**<u>5. FINANCING ARRANGEMENTS</u>** 

**Credit Facilities** 

Our multicurrency revolver credit facility (which amended and restated our prior U.S. Dollar-denominated revolving credit facility and replaced our prior Euro-denominated revolving credit facility (Multicurrency Revolver)) has a maximum capacity of $2.20 billion and matures in 2030. Borrowings under the Multicurrency Revolver in U.S. dollars bear interest on the principal amount outstanding at either Term SOFR plus an applicable margin or a "base rate" plus an applicable margin. The Multicurrency Revolver contains various covenants, including a maximum net leverage ratio. Borrowings in Euros are subject to a sublimit of $300 million. We may, at our option, seek to increase the aggregate commitment under the Multicurrency Revolver by up to $1.10 billion, which would result in a maximum aggregate commitment of up to $3.30 billion. There were no borrowings outstanding under the Multicurrency Revolver as of March 31, 2026 or December 31, 2025. Our commercial paper borrowing arrangements require us to maintain undrawn borrowing capacity under our Multicurrency Revolver for an amount at least equal to our outstanding commercial paper borrowings. Based on our covenant calculations as of March 31, 2026, we had capacity to draw $1.62 billion under the Multicurrency Revolver.

As of March 31, 2026, we were in compliance with the financial covenant in the Multicurrency Revolver. The non-performance of any financial institution supporting the Multicurrency Revolver would reduce the capacity thereunder by such institution's respective commitment.

**<u>6. COMMITMENTS AND CONTINGENCIES</u>** 

We are involved in product liability, patent, commercial, employment and other legal matters that arise in the normal course of our business. We record a liability when a loss is considered probable and the amount can be reasonably estimated. If the reasonable estimate of a probable loss is a range, and no amount within the range is a better

------

estimate than any other amount, the minimum amount in the range is accrued. If a loss is not probable or a probable loss cannot be reasonably estimated, no liability is recorded. We regularly review legal contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates and could have a material adverse effect on our results of operations and cash flows. As of March 31, 2026 and December 31, 2025, our total recorded reserves with respect to legal and environmental matters were $44 million and $47 million, respectively.

We have established reserves for certain of the matters discussed below. While we believe that we have valid defenses in the matters set forth below, litigation is inherently uncertain, excessive verdicts do occur, and we may incur material judgments or enter into material settlements of claims.

In addition to the matters described below, we remain subject to the risk of future administrative and legal actions. With respect to governmental and regulatory matters, these actions may lead to additional product recalls, injunctions, and other restrictions on our operations (including our ability to launch new products) and monetary sanctions, including significant civil or criminal penalties. With respect to intellectual property, we may be exposed to significant litigation concerning the scope of our and others' rights. Such litigation could result in a loss of patent protection or the ability to market products, which could lead to a significant loss of sales, or otherwise materially affect future results of operations.

**Novum IQ Large Volume Pump (Novum LVP)**

During 2025, we initiated certain voluntary corrections for the Novum LVP. The U.S. Food and Drug Administration (FDA) classified these voluntary corrections as Class I recalls. We have implemented certain corrections related to these recalls, and are developing additional corrections related to these recalls, some of which may require regulatory clearance or approval. In July 2025, we elected to temporarily stop distributing and installing the Novum LVP in the U.S. and Canada, except in the case of medical necessity. In 2025, we recorded estimates for sales reductions, for returns or exchanges of Novum LVP, and certain other charges, including estimates of reserves for remediation costs and inventory and contract asset write-downs associated with these Novum LVP corrections. We regularly review these estimates (including those associated with any future additional corrections and customer returns or exchanges), which may be subject to additional change in the future and these and other additional costs could become material in the future. In the first quarter of 2026, we adjusted certain estimates associated with these Novum LVP corrections that were not material to our condensed consolidated financial statements.

**Environmental**

We are involved as a potentially responsible party (PRP) for environmental clean-up costs at several Superfund sites. Under the U.S. Superfund statute and many state laws, generators of hazardous waste sent to a disposal or recycling site are liable for site cleanup if contaminants from that property later leak into the environment. The laws generally provide that a PRP may be held jointly and severally liable for the costs of investigating and remediating the site. Separate from these Superfund cases noted above, we are involved in ongoing environmental remediations associated with historic operations at certain of our facilities. As of March 31, 2026 and December 31, 2025, our environmental reserves, which are measured on an undiscounted basis, were $25 million and $29 million, respectively. After considering these reserves, the outcome of these matters is not expected to have a material adverse effect on our financial position or results of operations.

**General Litigation**

Since December 2023, lawsuits have been filed against us in the Circuit Court of Cook County, Illinois by plaintiffs alleging injuries as a result of exposure to ethylene oxide used by several companies, including historic use by us for sterilization at our facility in Round Lake, Illinois. Thirty-eight complaints are currently filed and pending. The parties have reached an agreement in principle to resolve these filed cases, for an amount not material to Baxter.

In October 2022, the DOJ issued a Civil Investigative Demand (CID) addressed to Hillrom, requesting documents and information related to compliance with the False Claims Act and the Anti-Kickback Statute. In October 2024, the DOJ issued a subpoena (the 2024 Subpoena), pursuant to 18 U.S.C. 3846, to Hillrom. The 2024 Subpoena substantially overlaps with the CID and requests additional documents relating to Hillrom's respiratory health business. Baxter is cooperating fully with the DOJ in responding to the CID and the 2024 Subpoena. The DOJ often issues these types of requests when investigating alleged violations of the federal health care laws.

------

In December 2021, Linet Americas, Inc. (Linet) filed a complaint against Hill-Rom Holdings, Inc., Hill-Rom Company, Inc., and Hill-Rom Services, Inc. in the United States District Court for the Northern District of Illinois. Linet alleges that Hillrom violated federal and state antitrust laws by allegedly engaging in anti-competitive conduct in alleged markets for standard, ICU and birthing beds. Hillrom filed an answer to the complaint in January 2022 and filed a motion challenging certain aspects of plaintiff's case in May 2022, which was denied in January 2024, subject to further discovery. Fact discovery is ongoing.

In June 2024, Reading Hospital filed a putative class action complaint against Hill-Rom Holdings, Inc., Hill-Rom Company, Inc., and Hill-Rom Services, Inc. in the United States District Court for the Eastern District of Pennsylvania. The complaint alleged that Hillrom violated federal antitrust laws by allegedly engaging in anti-competitive conduct in alleged markets for standard, ICU and birthing beds. The plaintiff filed the action on behalf of itself and all "direct purchasers of Standard Hospital Beds, ICU Beds, and/or Birthing Beds from Hill-Rom during a period beginning at least as early as June 20, 2020" and continuing past the date of filing. In September 2024, the plaintiff filed a First Amended Complaint. In November 2024, Hillrom filed a Motion to Dismiss Plaintiff's Amended Complaint. After briefing and a hearing, the court granted the motion and dismissed the case with prejudice in September 2025. Reading Hospital filed a Notice of Appeal of the dismissal in October 2025; appellate briefing is underway.

In October 2025, we and certain of our current and former officers and employees were named in a class action complaint captioned Electrical Workers Pension Fund, Local 103, I.B.E.W. v. Baxter International Inc. et al. that was filed in the United States District Court for the Northern District of Illinois. The plaintiff, which allegedly purchased or otherwise acquired shares of our common stock during the specified class period, filed this putative class action on behalf of itself and those who purchased or otherwise acquired Baxter common stock between February 23, 2022 and July 30, 2025. The plaintiff alleges that we and certain former and current officers and employees violated federal securities laws by making allegedly false and misleading statements and failing to disclose material facts relating to Novum LVP. In December 2025, an additional class action complaint was filed against us and certain of our current and former officers and employees in the United States District Court for the Northern District of Illinois, captioned City of Hallansdale Beach Police Officers' and Firefighters' Personnel Retirement Trust v. Baxter International Inc., et al. The additional complaint included substantially the same allegations for the expanded period from February 23, 2022, through October 29, 2025. Plaintiffs filed their respective motions to be appointed lead plaintiff in December 2025, which are pending before the court.

In November 2025, certain of our current and former directors, officers and employees were named in two derivative complaints in the United States District Court for the Northern District of Illinois, captioned Ryan Wood v. Jose E. Almeida, et al. and Kevin Gray v. Jose E. Almeida, et al., respectively. Both complaints allege, nominally on behalf of Baxter International Inc., breaches of fiduciary duties and violations of federal law in connection with public statements about Novum LVP. The two derivative complaints were consolidated before the court in January 2026.

In addition, we have received stockholder requests for inspections of our books and records in connection with statements made about Novum LVP.

In December 2025, we received a CID from the DOJ requesting documents and information related to production of Baxter's IV flexible containers and compliance with the False Claims Act. We are cooperating fully with the DOJ in responding to the CID.

**<u>7. STOCKHOLDERS' EQUITY</u>**

**Cash Dividends**

Cash dividends declared per share for the three months ended March 31, 2026 and 2025 were $0.01 and $0.17, respectively.

**Stock Repurchase Programs**

In July 2012, our Board of Directors authorized a share repurchase program and the related authorization amount was subsequently increased a number of times. During the first three months of 2026 and 2025 we did not repurchase any shares under this authority. We had $1.30 billion remaining available under the authorization as of March 31, 2026.

**<u>8. ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)</u>**

Comprehensive income (loss) represents net earnings plus items that are recorded directly to shareholders' equity, such as cumulative translation adjustments (CTA), certain gains and losses from pension and other postretirement

------

employee benefit (OPEB) plans, certain gains and losses from hedging activities and unrealized gains and losses on available-for-sale debt securities.

The following table is a net-of-tax summary of the changes in accumulated other comprehensive income (loss) (AOCI) by component for the three months ended March 31, 2026 and 2025.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | Gains (losses) | Gains (losses) | Gains (losses) | Gains (losses) | Gains (losses) |
| (in millions) | CTA | Pension and OPEB plans | Hedging activities | Available-for-sale debt securities | Total |
| Balance as of December 31, 2025 | $(3133) | $(514) | $(110) | $3 | $(3754) |
| &nbsp;&nbsp;Other comprehensive income (loss) before reclassifications | (52) | 1 |  |  | (51) |
| &nbsp;&nbsp;Amounts reclassified from AOCI <sup>(a)</sup> |  | 2 | 1 |  | 3 |
| Net other comprehensive income (loss) | (52) | 3 | 1 |  | (48) |
| Balance as of March 31, 2026 | $(3185) | $(511) | $(109) | $3 | $(3802) |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | Gains (losses) | Gains (losses) | Gains (losses) | Gains (losses) | Gains (losses) |
| (in millions) | CTA | Pension and OPEB plans | Hedging activities | Available-for-sale debt securities | Total |
| Balance as of December 31, 2024 | $(3430) | $(475) | $(108) | $3 | $(4010) |
| &nbsp;&nbsp;Other comprehensive income (loss) before reclassifications | (57) | 14 |  |  | (43) |
| &nbsp;&nbsp;Amounts reclassified from AOCI <sup>(a)</sup> | 126 | (13) | (2) |  | 111 |
| Net other comprehensive income (loss) | 69 | 1 | (2) |  | 68 |
| Balance as of March 31, 2025 | $(3361) | $(474) | $(110) | $3 | $(3942) |

---

(a)&nbsp;&nbsp;&nbsp;&nbsp;See table below for details about these reclassifications.

------

The following is a summary of the amounts reclassified from AOCI to net income (loss) during the three months ended March 31, 2026 and 2025.

---

| | | | |
|:---|:---|:---|:---|
| | Amounts reclassified from AOCI (a) | Amounts reclassified from AOCI (a) | |
| (in millions) | Three months ended March 31, 2026 | Three months ended March 31, 2025 | Location of impact in income statement |
| CTA |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Reclassification of cumulative translation loss to earnings from Kidney Care separation | $— | $(126) | Income from discontinued operations, net of tax |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: Tax effect |  |  | Income from discontinued operations, net of tax |
|  | $— | $(126) | Net of tax |
| Pension and OPEB items |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of net losses and prior service costs or credits | $(3) | $3 | Other (income) expense, net |
| &nbsp;&nbsp;&nbsp;&nbsp;Pension settlement from Kidney Care separation |  | 14 | Income from discontinued operations, net of tax |
|  | $(3) | $17 | Total before tax |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: Tax effect | 1 | (1) | Income tax expense (benefit) |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: Tax effect on pension settlement from Kidney Care separation |  | (3) | Income from discontinued operations, net of tax |
|  | $(2) | $13 | Net of tax |
| Gains (losses) on hedging activities |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign exchange contracts | $— | $(1) | Cost of sales |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest rate contracts | (1) | 4 | Interest expense, net |
|  | (1) | 3 | Total before tax |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: Tax effect |  | (1) | Income tax expense (benefit) |
|  | $(1) | $2 | Net of tax |
| Total reclassifications for the period | $(3) | $(111) | Total net of tax |

---

(a)&nbsp;&nbsp;&nbsp;&nbsp;Amounts in parentheses indicate reductions to net income

Refer to Note 11 for additional information regarding the amortization of pension and OPEB items and Note 14 for additional information regarding hedging activity.

**<u>9. REVENUES</u>**

Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or providing services. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in the contract. A contract's transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. Some of our contracts have multiple performance obligations. For contracts with multiple performance obligations, we allocate the contract's transaction price to each performance obligation using our best estimate of the standalone selling price of each distinct good or service in the contract. Our global payment terms are typically between 30 to 90 days.

Our primary customers are hospitals, healthcare distribution companies, and government agencies that purchase healthcare products on behalf of providers. Most of our performance obligations are satisfied at a point in time. This includes sales of our broad portfolio of essential healthcare products across our business segments. We earn revenues from sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; smart bed systems; patient monitoring and diagnostic technologies; respiratory health devices; and advanced equipment for the surgical space. For most of those offerings, our performance obligation is satisfied upon delivery to the customer. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation.

------

To a lesser extent, we enter into arrangements for which revenue may be recognized over time. For example, we lease medical equipment to customers under operating lease arrangements and recognize the related revenues on a monthly basis over the lease term. Our Healthcare Systems & Technologies segment includes connected care solutions and collaboration tools that are implemented over time. We recognize revenue for these arrangements over time or at a point in time depending on our evaluation of when the customer obtains control of the promised goods or services. We also earn revenue from contract manufacturing activities, which is recognized over time as the services are performed. Revenue is recognized over time when we are creating or enhancing an asset that the customer controls as the asset is created or enhanced or our performance does not create an asset with an alternative use and we have an enforceable right to payment for performance completed.

As of March 31, 2026, we had $8.87 billion of transaction price allocated to remaining performance obligations related to executed contracts with an original duration of more than one year, which are primarily included in the Medical Products & Therapies segment. Some contracts in the United States included in this amount contain index-dependent price increases, which are not known at this time. We expect to recognize approximately 25% of this amount as revenue over the remainder of 2026, 20% in 2027, 15% in each of 2028 and 2029, 10% in 2030 and the remainder thereafter.

**Significant Judgments**

Revenues from product sales are recorded at the net sales price, which include estimates of variable consideration primarily related to rebates and distributor chargebacks. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are included in accrued expenses and other current liabilities and as reductions of accounts receivable, net on the condensed consolidated balance sheets. Management's estimates take into consideration historical experience, current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract using the expected value method. The amount of variable consideration included in the net sales price is limited to the amount for which it is probable that a significant reversal in revenue will not occur when the related uncertainty is resolved. Revenue recognized during the three months ended March 31, 2026 and 2025 related to performance obligations satisfied in prior periods was not material. Additionally, our contracts with customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately and determining the allocation of the transaction price may require significant judgment.

**Contract Balances**

The timing of revenue recognition, billings and cash collections results in the recognition of trade accounts receivable, unbilled receivables, contract assets and customer advances, and deposits (contract liabilities) on our condensed consolidated balance sheets. Net trade accounts receivable was $1.54 billion and $1.70 billion as of March 31, 2026 and December 31, 2025, respectively.

For contract manufacturing arrangements, revenue is primarily recognized throughout the production cycle, which typically lasts up to 90 days, resulting in the recognition of contract assets until the related services are completed and the customers are billed. Additionally, for certain arrangements containing a performance obligation to deliver software that can be used with medical devices, we recognize revenue upon delivery of the software, which results in the recognition of contract assets when customers are billed over time, generally over one to five years. For bundled contracts involving equipment delivered up-front and consumable medical products to be delivered over time, total contract revenue is allocated between the equipment and consumable medical products. In certain of those arrangements, a contract asset is created for the difference between the amount of equipment revenue recognized upon delivery and the amount of consideration initially receivable from the customer. In those arrangements, the contract asset becomes a trade account receivable as consumable medical products are delivered and billed, generally over one to seven years.

------

The following table summarizes our contract assets:

---

| | | |
|:---|:---|:---|
| (in millions) | March 31,<br>2026 | December 31,<br>2025 |
| Contract manufacturing services | $5 | $3 |
| Software sales | 31 | 34 |
| Bundled equipment and consumable medical products contracts | 100 | 110 |
| Contract assets | $136 | $147 |

---

Contract liabilities represent deferred revenues that arise as a result of cash received from customers or where the timing of billing for services precedes satisfaction of our performance obligations. Such remaining performance obligations represent the portion of the contract price for which work has not been performed and are primarily related to our installation and service contracts. We expect to satisfy the majority of the remaining performance obligations and recognize revenue related to installation and service contracts within the next 12 months with most of the non-current performance obligations satisfied within 24 months.

The following table summarizes contract liability activity for the three months ended March 31, 2026 and 2025. The contract liability balance represents the transaction price allocated to the remaining performance obligations.

---

| | | |
|:---|:---|:---|
| | Three Months Ended March 31, | Three Months Ended March 31, |
| (in millions) | 2026 | 2025 |
| Balance at beginning of period | $177 | $171 |
| New revenue deferrals | 187 | 128 |
| Revenue recognized upon satisfaction of performance obligations | (182) | (124) |
| Currency translation and other |  |  |
| Balance at end of period | $182 | $175 |

---

For the three months ended March 31, 2026 and 2025, $46 million and $34 million of revenue was recognized that was included in contract liabilities as of December 31, 2025 and 2024, respectively.

The following table summarizes the classification of contract assets and contract liabilities as reported in the condensed consolidated balance sheets:

---

| | | |
|:---|:---|:---|
| (in millions) | March 31,<br>2026 | December 31,<br>2025 |
| Prepaid expenses and other current assets | $70 | $71 |
| Other non-current assets | 66 | 76 |
| Contract assets | $136 | $147 |
| Accrued expenses and other current liabilities | $152 | $141 |
| Other non-current liabilities | 30 | 36 |
| Contract liabilities | $182 | $177 |

---

**Disaggregation of Net Sales**

Refer to Note 16 for additional information on our net sales including the disaggregation of net sales within each of our segments and net sales by geographic location.

------

**Lease Revenue**

We lease medical equipment, such as smart beds and infusion pumps, to customers, often in conjunction with arrangements to provide consumable medical products such as IV fluids and inhaled anesthetics. Certain of our equipment leases are classified as sales-type leases and the remainder are operating leases. The terms of the related contracts, including the proportion of fixed versus variable payments and any options to shorten or extend the lease term, vary by customer. We allocate revenue between equipment leases and medical products based on their standalone selling prices.

The components of lease revenue for the three months ended March 31, 2026 and 2025 were:

---

| | | |
|:---|:---|:---|
| | Three Months Ended March 31, | Three Months Ended March 31, |
| (in millions) | 2026 | 2025 |
| Sales-type lease revenue | $3 | $8 |
| Operating lease revenue | 90 | 91 |
| Variable lease revenue | 7 | 7 |
| Total lease revenue | $100 | $106 |

---

Our net investment in sales-type leases was $30 million as of March 31, 2026, of which $5 million originated in 2022 and prior, $5 million in 2023, $9 million in 2024, $8 million in 2025, and $3 million in 2026.

**<u>10. BUSINESS OPTIMIZATION CHARGES</u>**

We are continuing to undertake actions to transform our cost structure and enhance operational efficiency. In recent years, these efforts have included restructuring the organization into verticalized segments, optimizing the manufacturing footprint, R&D operations and supply chain network, employing disciplined cost management, and centralizing and streamlining certain support functions, some of which are still ongoing. We currently expect to incur additional pre-tax cash costs, primarily related to the implementation of business optimization programs, of approximately $2 million through the completion of certain initiatives that are currently underway. We continue to pursue cost savings initiatives, including those intended to mitigate a portion of the dis-synergies that arose as a result of the sale of our Kidney Care business, and we expect to incur additional restructuring charges and costs in future periods to implement business optimization programs. For segment reporting, business optimization charges are unallocated expenses.

During the three months ended March 31, 2026 and 2025, we recorded the following charges related to business optimization programs.

---

| | | |
|:---|:---|:---|
| | Three Months Ended March 31, | Three Months Ended March 31, |
| (in millions) | 2026 | 2025 |
| Restructuring charges | $61 | $44 |
| Costs to implement business optimization programs<sup>1</sup> | 7 | 1 |
| Total business optimization charges | $68 | $45 |

---

<sup>1</sup>Costs to implement business optimization programs for the three months ended March 31, 2026 and 2025, respectively, consisted primarily of external consulting and transition costs, including employee compensation and related costs. These costs were primarily included within cost of sales and SG&A expense.

------

During the three months ended March 31, 2026 and 2025, we recorded the following restructuring charges.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | Three months ended March 31, 2026 | Three months ended March 31, 2026 | Three months ended March 31, 2026 | Three months ended March 31, 2026 |
| (in millions) | COGS | SG&A | R&D | Total |
| Employee termination costs | $10 | $35 | $13 | $58 |
| Contract termination and other costs | 1 |  | 1 | 2 |
| Asset write offs |  | 1 |  | 1 |
| Total restructuring charges | $11 | $36 | $14 | $61 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | Three months ended March 31, 2025 | Three months ended March 31, 2025 | Three months ended March 31, 2025 | Three months ended March 31, 2025 |
| (in millions) | COGS | SG&A | R&D | Total |
| Employee termination costs | $12 | $13 | $1 | $26 |
| Asset write offs | 1 | 17 |  | 18 |
| Total restructuring charges | $13 | $30 | $1 | $44 |

---

For the three months ended March 31, 2026 and 2025, $58 million and $25 million, respectively, of the restructuring charges reflected in the table above, consisting of employee termination costs, were related to initiatives to reduce our cost structure following the sale of our Kidney Care segment.

The following table summarizes activity in the liability related to our restructuring initiatives.

---

| | |
|:---|:---|
| (in millions) |  |
| Liability balance as of December 31, 2025 | $133 |
| Charges | 60 |
| Payments | (48) |
| Reserve adjustments |  |
| Currency translation | (1) |
| Liability balance as of March 31, 2026 | $144 |

---

Substantially all of our restructuring liabilities as of March 31, 2026 relate to employee termination costs, with the remaining liabilities attributable to contract termination costs. Substantially all of the cash payments for those liabilities are expected to be disbursed by the end of 2026.

**<u>11. PENSION AND OTHER POSTRETIREMENT BENEFIT PROGRAMS</u>**

The following is a summary of net periodic benefit cost relating to our pension and OPEB plans.

---

| | | |
|:---|:---|:---|
| | Three Months Ended March 31, | Three Months Ended March 31, |
| (in millions) | 2026 | 2025 |
| <u>Pension benefits</u> |  |  |
| Service cost | $3 | $3 |
| Interest cost | 31 | 34 |
| Expected return on plan assets | (42) | (44) |
| Amortization of net losses and prior service costs | 3 | 1 |
| Net periodic pension cost (benefit) | $(5) | $(6) |
| <u>OPEB</u> |  |  |
| Interest cost | $1 | $2 |
| Amortization of net loss and prior service credit |  | (4) |
| Net periodic OPEB cost (income) | $1 | $(2) |

---

**<u>12. INCOME TAXES</u>**

Our effective income tax rate can differ from the 21% U.S. federal statutory rate due to a number of factors, including foreign rate differences, tax incentives, non-deductible expenses, non-taxable income, increases or decreases in

------

valuation allowances, increases or decreases in liabilities for uncertain tax positions, and excess tax benefits or shortfalls on stock compensation awards.

For the three months ended March 31, 2026, the difference between our effective income tax rate and the U.S. federal statutory rate was primarily driven by our near break-even pre-tax results and increases to our valuation allowance on U.S. deferred tax assets. The quarter also reflects income tax recorded related to tax shortfalls on stock compensation awards.

For the three months ended March 31, 2025, the difference between our effective income tax rate and the U.S. federal statutory rate was primarily driven by our near break-even pre-tax income and a tax benefit driven by an entity classification election that we made for U.S. tax purposes, which resulted in a capital loss.

We are currently under examination by the Internal Revenue Service (IRS) for transfer pricing matters related to transactions with our manufacturing operations in Costa Rica and Puerto Rico for the 2019 and 2020 tax years. During the quarter, we received a Notice of Proposed Adjustment (NOPA) from the IRS covering the 2019 and 2020 tax years that is consistent with our existing and previously disclosed uncertain tax position reserves. We did not record adjustments to the reserves in connection with the NOPA, other than interest that may be owed upon conclusion of the audit.

**<u>13. EARNINGS PER SHARE</u>**

The numerator for both basic and diluted earnings per share (EPS) is net income (loss) attributable to Baxter stockholders. The denominator for basic EPS is the weighted-average number of shares outstanding during the period. The dilutive effect of outstanding stock options, restricted stock units (RSUs) and performance share units (PSUs) is reflected in the denominator for diluted EPS using the treasury stock method.

The following table is a reconciliation of income (loss) from continuing operations to net income (loss) attributable to Baxter stockholders.

---

| | | |
|:---|:---|:---|
| | Three Months Ended March 31, | Three Months Ended March 31, |
| (in millions) | 2026 | 2025 |
| Income (loss) from continuing operations | $(17) | $64 |
| Less: Net income attributable to noncontrolling interests included in continuing operations |  |  |
| &nbsp;&nbsp;Income (loss) from continuing operations attributable to Baxter stockholders | (17) | 64 |
| Income (loss) from discontinued operations | 2 | 62 |
| Less: Net income attributable to noncontrolling interests included in discontinued operations |  |  |
| &nbsp;&nbsp;Income (loss) from discontinued operations attributable to Baxter stockholders | 2 | 62 |
| &nbsp;&nbsp;Net income (loss) attributable to Baxter stockholders | $(15) | $126 |

---

The following table is a reconciliation of basic shares and diluted shares.

---

| | | |
|:---|:---|:---|
| | Three Months Ended March 31, | Three Months Ended March 31, |
| (in millions) | 2026 | 2025 |
| Basic shares | 515 | 512 |
| Effect of dilutive securities |  | 2 |
| &nbsp;&nbsp;Diluted shares | 515 | 514 |

---

Basic and diluted shares are the same for three months ended March 31, 2026 due to our loss from continuing operations attributable to Baxter stockholders. The effect of dilutive securities includes unexercised stock options, unvested RSUs and contingently issuable shares related to granted PSUs. The computation of diluted EPS excludes 25 million and 20 million shares issuable under equity awards for the three months ended March 31, 2026 and 2025, respectively, because their inclusion would have had an anti-dilutive effect on diluted EPS.

------

**<u>14. DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES</u>**

We operate on a global basis and are exposed to the risk that our earnings, cash flows and equity could be adversely impacted by fluctuations in foreign exchange and interest rates. Our hedging policy attempts to manage these risks to an acceptable level based on our judgment of the appropriate trade-off between risk, opportunity and costs.

We are primarily exposed to foreign exchange risk with respect to recognized assets and liabilities, forecasted transactions and net assets denominated in the Euro, Polish Zloty, Swedish Krona, Swiss Franc, Turkish Lira, Australian Dollar, Singapore Dollar, Korean Wan, Chinese Renminbi, and Canadian Dollar. We manage our foreign currency exposures on a consolidated basis, which allows us to net exposures and take advantage of any natural offsets. In addition, we use derivative and nonderivative instruments to further reduce the net exposure to foreign exchange risk. Gains and losses on the hedging instruments offset losses and gains on the hedged transactions and reduce the earnings and equity volatility resulting from changes in foreign exchange rates. Financial market and currency volatility may limit our ability to cost-effectively hedge these exposures.

We are also exposed to the risk that our earnings and cash flows could be adversely impacted by fluctuations in interest rates. Our policy is to manage interest costs using the mix of fixed- and floating-rate debt that we believe is appropriate at that time. To manage this mix in a cost-efficient manner, we periodically enter into interest rate swaps in which we agree to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional amount.

We do not hold any instruments for trading purposes and none of our outstanding derivative instruments contain credit-risk-related contingent features.

Derivative instruments are recognized as either assets or liabilities at fair value in the condensed consolidated balance sheets and are classified as short-term or long-term based on the scheduled maturity of the instrument. We designate certain of our derivatives and foreign-currency denominated debt as hedging instruments in cash flow, fair value or net investment hedges.

<u>Cash Flow Hed</u>g<u>es</u>

We may use options, including collars and purchased options, forwards and cross-currency swaps to hedge the foreign exchange risk to earnings relating to forecasted transactions and recognized assets and liabilities. We periodically use treasury rate locks to hedge the risk to earnings associated with movements in interest rates relating to anticipated issuances of debt.

For each derivative instrument that is designated and effective as a cash flow hedge, the gain or loss on the derivative is recorded in AOCI and then recognized in earnings consistent with the underlying hedged transaction. Cash flow hedges are classified in cost of sales and interest expense, net, and are primarily related to forecasted intra-company sales denominated in foreign currencies and forecasted interest payments on anticipated issuances of debt, respectively.

There were no foreign exchange contracts designated as cash flow hedges outstanding as of March 31, 2026 and December 31, 2025. There were no outstanding interest rate contracts designated as cash flow hedges as of March 31, 2026 and December 31, 2025.

<u>Fair Value Hed</u>g<u>es</u>

We periodically use interest rate swaps to convert a portion of our fixed-rate debt into variable-rate debt. These instruments hedge our earnings from changes in the fair value of debt due to fluctuations in the designated benchmark interest rate.

There were no outstanding interest rate contracts designated as fair value hedges as of March 31, 2026 and December 31, 2025.

<u>Net Investment Hed</u>g<u>es</u>

In May 2017, we issued €600 million of 1.3% senior notes due May 2025. We had designated these debt obligations as hedges of our net investment in our European operations and, as a result, mark to spot rate adjustments of the outstanding debt balances were previously recorded as a component of AOCI. In March 2025, we dedesignated this

------

previously designated net investment hedge and concurrently entered into forward contracts to manage foreign exchange risk in earnings relating to these outstanding debt balances. These forward contracts matured in May 2025.

In May 2019, we issued €750 million of 1.3% senior notes due May 2029. We have designated these debt obligations as hedges of our net investment in our European operations and, as a result, mark to spot rate adjustments on the outstanding debt balances are recorded as a component of AOCI.

As of March 31, 2026, we had an accumulated pre-tax unrealized translation gain in AOCI of $17 million related to the Euro-denominated senior notes.

<u>Dedesignations</u>

If it is determined that a derivative or nonderivative hedging instrument is no longer highly effective as a hedge, we discontinue hedge accounting prospectively. Gains or losses relating to terminations of effective cash flow hedges generally continue to be deferred and are recognized consistent with the loss or income recognition of the underlying hedged transactions. However, if it is probable that the hedged forecasted transactions will not occur, any gains or losses would be immediately reclassified from AOCI to earnings.

There were no cash flow hedge dedesignations in the first three months of 2026 or 2025 resulting from changes in our assessment of the probability that the hedged forecasted transactions would occur.

If we terminate a fair value hedge, an amount equal to the cumulative fair value adjustment to the hedged item at the date of termination is amortized to earnings over the remaining term of the hedged item. There were no fair value hedges terminated during the first three months of 2026 or 2025.

If we remove a net investment hedge designation, any gain or loss recognized in AOCI is not reclassified to earnings until we sell, liquidate, or deconsolidate the foreign investments that were being hedged. There were no net investment hedges terminated during the first three months of 2026. In March 2025, we dedesignated one of our net investment hedges as discussed in the "Net Investment Hedges" section above.

<u>Undesignated Derivative Instruments</u>

We use forward contracts to hedge earnings from the effects of foreign exchange relating to certain of our intra-company and third-party receivables and payables denominated in a foreign currency. These derivative instruments are generally not formally designated as hedges and the terms of these instruments generally do not exceed one month.

In March 2025, as discussed in the "Net Investment Hedges" section above, we entered into forward contracts with a notional amount of $655 million to hedge the repayment of our Euro-denominated senior notes due May 2025. These forward contracts matured in May 2025. The total notional amount of undesignated derivative instruments was $187 million as of March 31, 2026 and $323 million as of December 31, 2025.

<u>Gains and Losses on Hedging Instruments and Undesignated Derivative Instruments</u>

The following tables summarize the gains and losses on our hedging instruments and the classification of those gains and losses within our condensed consolidated financial statements for the three months ended March 31, 2026 and 2025.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | Gain (loss) recognized in OCI | Gain (loss) recognized in OCI | Location of gain (loss)<br>in income statement | Gain (loss) reclassified from AOCI into income | Gain (loss) reclassified from AOCI into income |
| (in millions) | 2026 | 2025 | Location of gain (loss)<br>in income statement | 2026 | 2025 |
| **Cash flow hedges** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest rate contracts | $— | $— | Interest expense, net | $(1) | $(1) |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign exchange contracts |  |  | Cost of sales |  | 4 |
| **Net investment hedges** | 20 | 61 | Other (income) expense, net |  |  |
| Total | $20 | $61 |  | $(1) | $3 |

---

------

---

| | | | |
|:---|:---|:---|:---|
| | Location of gain (loss) in income statement | Gain (loss) recognized in income | Gain (loss) recognized in income |
| (in millions) | Location of gain (loss) in income statement | 2026 | 2025 |
| **Undesignated derivative instruments** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign exchange contracts | Other (income) expense, net | $(4) | $(2) |
| Total |  | $(4) | $(2) |

---

As of March 31, 2026, $4 million of deferred, net after-tax losses on derivative instruments included in AOCI are expected to be recognized in earnings during the next 12 months, coinciding with when the hedged items are expected to impact earnings.

<u>Derivative Assets and Liabilities</u>

The following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of March 31, 2026.

---

| | | |
|:---|:---|:---|
| | Derivatives in liability positions | Derivatives in liability positions |
| (in millions) | Balance sheet location | Fair value |
| **Derivative instruments designated as hedges** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net investment hedges | Long-term debt and finance lease obligations, less current portion | $805 |
| **Undesignated derivative instruments** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign exchange contracts | Accrued expenses and other current liabilities | 2 |
| Total derivative instruments |  | $807 |

---

The following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of December 31, 2025.

---

| | | |
|:---|:---|:---|
| | Derivatives in liability positions | Derivatives in liability positions |
| (in millions) | Balance sheet location | Fair value |
| **Derivative instruments designated as hedges** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net investment hedges | Long-term debt and finance lease obligations, less current portion | 834 |
| **Undesignated derivative instruments** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign exchange contracts | Accrued expenses and other current liabilities | 1 |
| Total derivative instruments |  | $835 |

---

While some of our derivatives are subject to master netting arrangements, we present our assets and liabilities related to derivative instruments on a gross basis within the condensed consolidated balance sheets. Additionally, we are not required to post collateral for any of our outstanding derivatives.

------

The following table provides information on our derivative positions as if they were presented on a net basis, allowing for the right of offset by counterparty.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | March 31, 2026 | March 31, 2026 | December 31, 2025 | December 31, 2025 |
| (in millions) | Asset | Liability | Asset | Liability |
| Gross amounts recognized in the condensed consolidated balance sheets | $— | $2 | $— | $1 |
| Gross amount subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet |  |  |  |  |
| Total | $— | $2 | $— | $1 |

---

The following table presents the amounts recorded on the condensed consolidated balance sheet related to fair value hedges:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | Carrying amount of hedged item | Carrying amount of hedged item | Cumulative amount of fair value hedging adjustment included<br> in the carrying amount of the hedged item (a) | Cumulative amount of fair value hedging adjustment included<br> in the carrying amount of the hedged item (a) |
| (in millions) | Balance as of March 31, 2026 | Balance as of December 31, 2025 | Balance as of March 31, 2026 | Balance as of December 31, 2025 |
| Long-term debt | $99 | $99 | $1 | $2 |

---

(a) These fair value hedges were terminated in 2018 and earlier periods.

**<u>15. FAIR VALUE MEASUREMENTS</u>**

The following tables summarize our assets and liabilities that are measured at fair value on a recurring basis.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | | Basis of fair value measurement | Basis of fair value measurement | Basis of fair value measurement |
| (in millions) | Balance as of March 31, 2026 | Quoted prices in active markets for identical assets<br>(Level 1) | Significant other<br>observable inputs<br>(Level 2) | Significant<br>unobservable inputs<br>(Level 3) |
| **Assets** |  |  |  |  |
| Foreign exchange contracts | $— | $— | $— | $— |
| Available-for-sale debt securities | 1 |  |  | 1 |
| Marketable equity securities | 11 | 11 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $12 | $11 | $— | $1 |
| **Liabilities** |  |  |  |  |
| Foreign exchange contracts | $2 | $— | $2 | $— |
| Contingent payments related to acquisitions | 7 |  |  | 7 |
| Indemnifications related to Kidney Care separation<sup>1</sup> | 53 |  |  | 53 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $62 | $— | $2 | $60 |

---

<sup>1</sup> See Note 2 for additional information.

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| | | Basis of fair value measurement | Basis of fair value measurement | Basis of fair value measurement |
| (in millions) | Balance as of December 31, 2025 | Quoted prices in active markets for identical assets<br>(Level 1) | Significant other<br>observable inputs<br>(Level 2) | Significant<br>unobservable inputs<br>(Level 3) |
| **Assets** |  |  |  |  |
| Available-for-sale debt securities | 1 |  |  | 1 |
| Marketable equity securities | 15 | 15 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $16 | $15 | $— | $1 |
| **Liabilities** |  |  |  |  |
| Foreign exchange contracts | $1 | $— | $1 | $— |
| Contingent payments related to acquisitions | 7 |  |  | 7 |
| Indemnifications related to Kidney Care separation<sup>1</sup> | 53 |  |  | 53 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $61 | $— | $1 | $60 |

---

As of March 31, 2026 and December 31, 2025, cash and cash equivalents of $2.02 billion and $1.97 billion, respectively, included money market fund and other short-term funds of approximately $853 million and $832 million, respectively, that are considered Level 2 in the fair value hierarchy.

For assets that are measured using quoted prices in active markets, the fair value is the published market price per unit multiplied by the number of units held, without consideration of transaction costs. A majority of the derivatives entered into by us are valued using internal valuation techniques as no quoted market prices exist for such instruments. The principal techniques used to value these instruments are discounted cash flow and Black-Scholes models. The key inputs, which are considered observable and vary depending on the type of derivative, include contractual terms, interest rate yield curves, foreign exchange rates and volatility.

Available-for-sale debt securities, which consist of convertible debt and convertible redeemable preferred shares issued by nonpublic entities, are measured using discounted cash flow and option pricing models. Those available-for-sale debt securities are classified as Level 3 fair value measurements when there are no observable transactions near the balance sheet date due to the lack of observable data over certain fair value inputs such as equity volatility. The fair values of available-for-sale debt securities increase when interest rates decrease, equity volatility increases, or the fair values of the equity shares underlying the conversion options increase.

Contingent payments related to acquisitions, which consist of milestone payments and sales-based payments, are valued using discounted cash flow techniques incorporating management's expectations of future outcomes. The fair value of milestone payments increases as the estimated probability of payment increases or the expected timing of payments is accelerated. The fair value of sales-based payments is based upon probability-weighted future revenue estimates, and increases as revenue estimates increase, probability weighting of higher revenue scenarios increases or the expected timing of payment is accelerated.

In addition, we have contingent payments related to the Kidney Care separation, which consist of reimbursements to Vantive for certain indemnifications contemplated in the EPA. For additional information on these items see Note 2.

The following table is a reconciliation of recurring fair value measurements that use significant unobservable inputs (Level 3), which consist of indemnifications related to the Kidney Care separation, contingent payments related to acquisitions and available-for-sale debt securities.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | Three Months Ended March 31, | Three Months Ended March 31, | Three Months Ended March 31, | Three Months Ended March 31, | Three Months Ended March 31, | Three Months Ended March 31, |
| | 2026 | 2026 | 2026 | 2025 | 2025 | 2025 |
| (in millions) | Indemnifications related to Kidney Care separation | Contingent payments related to acquisitions | Available-for-sale debt securities | Indemnifications related to Kidney Care separation | Contingent payments related to acquisitions | Available-for-sale debt securities |
| Fair value at beginning of period | $53 | $7 | $— | $— | $12 | $1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Additions |  |  |  | 37 |  |  |
| Fair value at end of period | $53 | $7 | $— | $37 | $12 | $1 |

---

------

<u>Financial Instruments Not Measured at Fair Value</u>

In addition to the financial instruments that we are required to recognize at fair value in the condensed consolidated balance sheets, we have certain financial instruments that are recognized at amortized cost or some basis other than fair value. For these financial instruments, the following table provides the values recognized in the condensed consolidated balance sheets and the estimated fair values as of March 31, 2026 and December 31, 2025.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | Book values | Book values | Fair values(a) | Fair values(a) |
| (in millions) | 2026 | 2025 | 2026 | 2025 |
| **Liabilities** |  |  |  |  |
| Current maturities of long-term debt and finance lease obligations | 842 |  | 823 | $— |
| Long-term debt and finance lease obligations | 8621 | 9436 | 7749 | 8714 |

---

(a)&nbsp;&nbsp;&nbsp;&nbsp;These fair value amounts are classified as Level 2 within the fair value hierarchy as they are estimated based on observable inputs.

The estimated fair values of current and long-term debt were computed by multiplying price by the notional amount of the respective debt instruments. Price is calculated using the stated terms of the respective debt instrument and yield curves commensurate with our credit risk. The carrying values of other financial instruments not presented in the above table, such as accounts receivable and accounts payable, approximate their fair values due to the short-term maturities of most of those assets and liabilities.

*Investments Without Readily Determinable Fair Values*

The carrying values of equity investments without readily determinable fair values that we measure at cost, less impairment were $45 million and $50 million as of as of March 31, 2026 and December 31, 2025, respectively. When applicable, we also adjust the measurement of such equity investments for observable prices in orderly transactions for an identical or similar investment of the same issuer. These investments are included in Other non-current assets on our condensed consolidated balance sheets.

**<u>16. SEGMENT INFORMATION</u>**

Our business is comprised of three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. The Medical Products & Therapies segment includes sales of our sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems & Technologies segment includes sales of our connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. Other sales not allocated to a segment primarily includes sales to Vantive, pursuant to the Kidney Care MSA, and sales of products and services provided directly through certain of our manufacturing facilities.

------

**Disaggregation of Net Sales**

The following table presents our U.S. and international disaggregated net sales.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | Three Months Ended March 31, | Three Months Ended March 31, | Three Months Ended March 31, | Three Months Ended March 31, | Three Months Ended March 31, | Three Months Ended March 31, |
| | 2026 | 2026 | 2026 | 2025 | 2025 | 2025 |
| (in millions) | U.S. | International | Total | U.S. | International | Total |
| Infusion Therapies & Technologies | $526 | $455 | $981 | $584 | $410 | $994 |
| Advanced Surgery | 165 | 139 | 304 | 145 | 123 | 268 |
| &nbsp;&nbsp;Medical Products & Therapies | 691 | 594 | 1285 | 729 | 533 | 1262 |
| Care & Connectivity Solutions | 315 | 120 | 435 | 316 | 111 | 427 |
| Front Line Care | 198 | 72 | 270 | 202 | 75 | 277 |
| &nbsp;&nbsp;Healthcare Systems & Technologies | 513 | 192 | 705 | 518 | 186 | 704 |
| Injectables & Anesthesia | 180 | 121 | 301 | 195 | 140 | 335 |
| Drug Compounding |  | 320 | 320 |  | 246 | 246 |
| &nbsp;&nbsp;Pharmaceuticals | 180 | 441 | 621 | 195 | 386 | 581 |
| &nbsp;&nbsp;Other | 51 | 39 | 90 | 48 | 30 | 78 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Baxter | $1435 | $1266 | $2701 | $1490 | $1135 | $2625 |

---

**Segment Operating Income**

Our chief operating decision maker who has been identified as our President and Chief Executive Officer, reviews the financial information presented for purposes of evaluating the performance of our segments and to make resource allocation decisions.

Segment operating income is the measure of segment profitability and represents income before income taxes, interest and other non-operating income or expense, unallocated corporate costs, intangible asset amortization, and other special items. Special items, which are presented below in our reconciliations of reportable segment operating income to income (loss) from continuing operations before income taxes, are excluded from segment operating income because they are highly variable, difficult to predict and of a size that may substantially impact our reported results of operations for the period.

Corporate costs, inclusive of global functional support costs, overhead costs and other shared costs that benefit our segments are allocated to those segments. Corporate costs that are not allocated to our segments, as well as any differences between actual corporate costs and the amounts allocated to our segments, are presented as unallocated corporate costs.

Segment results include net sales, cost of sales, selling, general and administrative expenses, R&D expenses, corporate costs that had previously been allocated to our former Kidney Care segment which did not convey in the related sale, and other segment items which are directly allocated to each segment. Billings by us under the Kidney

------

Care TSA are included in other segment items as further described in Note 2. The following table presents our segment information of net sales, significant expenses and operating income during the periods presented.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2025 |
| (in millions) | Medical Products & Therapies | Healthcare Systems & Technologies | Pharmaceuticals | Medical Products & Therapies | Healthcare Systems & Technologies | Pharmaceuticals |
| Net sales | $1285 | $705 | $621 | $1262 | $704 | $581 |
| Cost of sales | 781 | 390 | 458 | 694 | 356 | 396 |
| Selling, general and administrative expenses | 290 | 209 | 102 | 286 | 217 | 103 |
| Research and development expenses | 54 | 49 | 22 | 59 | 45 | 26 |
| Other segment items | (26) | (9) | (7) | (21) | (7) | (7) |
| Segment operating income | $186 | $66 | $46 | $244 | $93 | $63 |

---

The following table presents our reportable segment operating income and reconciliations of reportable segment operating income to income (loss) from continuing operations before income taxes.

---

| | | |
|:---|:---|:---|
| | Three Months Ended March 31, | Three Months Ended March 31, |
| (in millions) | 2026 | 2025 |
| Medical Products & Therapies | $186 | $244 |
| Healthcare Systems & Technologies | 66 | 93 |
| Pharmaceuticals | 46 | 63 |
| Total reportable segment operating income | 298 | 400 |
| &nbsp;&nbsp;Other | 11 | 9 |
| &nbsp;&nbsp;Unallocated corporate costs | (12) | (17) |
| &nbsp;&nbsp;Intangible asset amortization expense | (146) | (155) |
| &nbsp;&nbsp;Legal matters |  | (11) |
| &nbsp;&nbsp;Business optimization items | (68) | (45) |
| &nbsp;&nbsp;Acquisition and integration items |  | (1) |
| &nbsp;&nbsp;Separation-related costs | (11) | (13) |
| &nbsp;&nbsp;European Medical Devices Regulation | (4) | (5) |
| &nbsp;&nbsp;Business transformation | (11) |  |
| &nbsp;&nbsp;Hurricane Helene costs | (3) | (98) |
| &nbsp;&nbsp;Product-related items | 12 | (6) |
| Total operating income | 66 | 58 |
| &nbsp;&nbsp;Interest expense, net | 66 | 64 |
| &nbsp;&nbsp;Other (income) expense, net | 6 | (3) |
| Income (loss) from continuing operations before income taxes | $(6) | $(3) |

---

Additional financial information for our segments is as follows:

---

| | | |
|:---|:---|:---|
| | Three Months Ended March 31, | Three Months Ended March 31, |
| (in millions) | 2026 | 2025 |
| Depreciation Expense<sup>1</sup> |  |  |
| &nbsp;&nbsp;Medical Products & Therapies | $51 | $49 |
| &nbsp;&nbsp;Healthcare Systems & Technologies | 24 | 27 |
| &nbsp;&nbsp;Pharmaceuticals | 16 | 16 |
| Total depreciation expense | $91 | $92 |

---

------

<sup>1</sup>Depreciation expense related to Corporate property, plant and equipment has been fully allocated to our segments and those segment allocations are reflected in the depreciation amounts presented herein.

Our CODM does not receive asset information by reportable segment and, accordingly, we do not report that information for our segments.

------

Item 2.&nbsp;&nbsp;&nbsp;&nbsp;Management's Discussion and Analysis of Financial Condition and Results of Operations

Refer to our Annual Report on Form 10-K for the year ended December 31, 2025 (2025 Annual Report) for management's discussion and analysis of our financial condition and results of operations. The following is management's discussion and analysis of our financial condition and results of operations for the three months ended March 31, 2026 and 2025.

**<u>COMPLETED STRATEGIC ACTION; ONGOING BUSINESS TRANSFORMATION</u>**

On January 31, 2025, we completed the sale of our former Kidney Care segment (which is now known as Vantive Health LLC (Vantive)) to certain affiliates of Carlyle Group Inc. (Carlyle) and ultimately received approximately $3.2 billion of after-tax cash proceeds that were used to repay short- and long-term legacy indebtedness in 2025.

We have incurred and expect to incur additional dis-synergies following our sale of our Kidney Care business due to the reduced size of our company and, as a result, we have undertaken certain restructuring actions (and intend to undertake additional actions) to help ensure our cost structuring is appropriate to support our remaining business. See Note 10 of this Quarterly Report on Form 10-Q for additional information.

Additionally, we continue to evolve our operating model to better align decision-making, cost structure, and commercial execution across our businesses. As part of this work, we continue to focus on increasing efficiencies through increased automation and digitization (including through our thoughtful exploration of artificial intelligence initiatives). Beginning in October 2025, we launched Baxter Growth and Performance system, our high performance business system grounded in continuous improvement and management by objectives.

**FACTORS AFFECTING OUR RESULTS OF OPERATIONS**

**Novum IQ Large Volume Pump (Novum LVP)**

During 2025, we initiated voluntary corrections for the Novum LVP. The U.S. Food and Drug Administration (FDA) classified these voluntary corrections as Class I recalls. We have implemented certain corrections related to the recalls, and are developing additional corrections related to these recalls, some of which may require regulatory clearance or approval. In July 2025, we elected to temporarily stop distributing and installing the Novum LVP in the U.S. and Canada, except in the case of medical necessity. The timing of the release of the ship and installation hold remains uncertain. As a result, we expect no meaningful sales of Novum LVP while these holds are in effect. Our Spectrum IQ large volume pump remains available as an alternative option for customers with Novum LVPs. In 2025, we recorded estimates for sales reductions, for returns or exchanges of Novum LVP, and certain other charges, including estimates of reserves for remediation costs and inventory and contract asset write-downs associated with these Novum LVP corrections. We regularly review these estimates (including those associated with any future additional corrections and customer returns or exchanges), which may be subject to additional change in the future. In the first quarter of 2026, we adjusted certain estimates associated with these Novum LVP corrections that were not material to our condensed consolidated financial statements.

**Supply Constraints, Tariffs and Global Economic Conditions** 

We have experienced challenges to our global supply chain, including, as a result of adverse impacts from significant weather events like Hurricane Helene and other global macroeconomic and geopolitical events, which have had a negative impact on our results of operations and may do so in the future. In addition, announcements regarding changes in U.S. trade policies and practices, including the implementation of global tariffs and proposed further tariffs (including potential medical device and pharmaceutical tariffs), the Supreme Court's decision to invalidate tariffs levied under the International Emergency Economic Powers Act, and responses from other jurisdictions, have significantly affected financial markets and economic conditions. While in the second quarter of 2026 we submitted refund requests for those tariff amounts eligible for refund in the first phase of the process and expect to submit additional refund requests in future phases subject to further rulings by the Court of International Trade, uncertainty remains surrounding the economic impact of the global tariffs and the timing and quantum of any amounts we may ultimately recover on our refund claims, and therefore, we have not recorded an asset for tariff refunds in our condensed consolidated financial statements as of March 31, 2026. We currently expect that our results will continue to be adversely impacted by Section 122 duties that were imposed following the judicial review of certain tariffs. Additionally, continued global macroeconomic uncertainty, including in trade policies and practices, elevated tariffs and operational and policy changes in the governments of the U.S. and other countries and other geopolitical events or conflicts (including the conflict in Iran and the potential for escalation of this and other conflicts), could contribute to further

------

market volatility, deteriorating or prolonged weakened economic conditions and decreased hospital capital spending levels. We continue to closely monitor these developing situations and the estimated impact on our business, results of operations, financial condition and cash flows.

Over the past few years, the existence of high inflation rates in the United States and in many of the countries where we conduct business has resulted in, and may in the future result in, higher interest rates, shipping costs, labor costs, and other costs and expenses. Additionally, adverse changes in foreign currency exchange rates have increased, and could continue to increase, our costs of sourcing certain raw materials in some jurisdictions. We have experienced and are likely in the future to experience inflationary and other increases in manufacturing costs and operating expenses (including as a result of the aforementioned tariffs) and are limited in our ability to pass these cost increases on to our customers in a timely manner or at all due to the longer term nature of our customer contracts and arrangements, which could have a material adverse impact on our profitability and results of operations. Inflation and general macroeconomic factors have caused certain of our customers to reduce or delay orders for our products and services and could cause them to do so in the future, which could have a material adverse impact on our sales and results of operations.

For further discussion, please refer to Item 1A, Risk Factors in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025.

**NON-GAAP FINANCIAL MEASURES**

Our presentation of percentage changes in net sales at organic sales growth excludes the impact of the Kidney Care MSA sales not reflected in reportable segments, impacts associated with business acquisitions or divestitures, and is calculated at constant currency rates. Constant currency rates are computed using current period local currency sales at the prior period's foreign exchange rates. Organic sales growth is a non-GAAP financial measure. This measure provides information about growth (or declines) in our net sales as if the Kidney Care MSA had no impact on our sales and foreign currency exchange rates had not changed between the prior period and the current period. We believe that the non-GAAP measure of percent change in net sales at organic sales growth, when used in conjunction with the U.S. GAAP measure of percent change in net sales at actual rates, may provide a more complete understanding and facilitate a fuller analysis of our results of operations, particularly in evaluating performance from one period to another.

**<u>RESULTS OF OPERATIONS</u>**

Net income (loss) attributable to Baxter stockholders for the three months ended March 31, 2026 was $(15) million, or $(0.03) per diluted share, compared to $126 million, or $0.25 per diluted share for the three months ended March 31, 2025. For the three months ended March 31, 2026, our results included special items that adversely impacted net income (loss) attributable to Baxter stockholders by $205 million, or $0.40 per diluted share. For the three months ended March 31, 2025, our results included special items that adversely impacted net income (loss) attributable to Baxter stockholders by $194 million, or $0.37 per diluted share.

Net income (loss) from continuing operations for the three months ended March 31, 2026 was $(17) million, or $(0.03) per diluted share, compared to $64 million, or $0.13 per diluted share for the three months ended March 31, 2025. Net income (loss) from continuing operations for the three months ended March 31, 2026 included special items that adversely impacted net income (loss) by $205 million, or $0.39 per diluted share. Net income (loss) from continuing operations for the three months ended March 31, 2025 included special items that adversely impacted net income (loss) by $221 million, or $0.42 per diluted share.

See the subsection entitled "Special Items" for information about special items for all periods presented.

------

**CONSOLIDATED NET SALES**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | Three Months Ended March 31, | Three Months Ended March 31, | Percent change | Percent change |
| (in millions) | 2026 | 2025 | At actual<br>rates | At organic sales growth <sup>1</sup> |
| United States | $1435 | $1490 | (4)% | (4)% |
| International | 1266 | 1135 | 12% | 3% |
| Total net sales | $2701 | $2625 | 3% | (1)% |

---

1 &nbsp;&nbsp;&nbsp;&nbsp;Percent change in net sales at organic sales growth is a non-GAAP financial measure. See the section entitled "Non-GAAP Financial Measures" for additional information about our use of that measure.

In the first quarter of 2026, the Kidney Care MSA sales favorably impacted sales growth by 1%. Additionally, in the first quarter of 2026, foreign currency rates favorably impacted net sales growth by 3%, compared to the prior year period due to the strengthening of the U.S. Dollar relative to the Euro, Australian Dollar, British Pound and the Canadian Dollar.

**NET SALES BY SEGMENT**

**Medical Products & Therapies**

Our Medical Products & Therapies segment includes sales of our sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | Three Months Ended March 31, | Three Months Ended March 31, | Percent change | Percent change |
| (in millions) | 2026 | 2025 | At actual<br>rates | At organic sales growth <sup>1</sup> |
| Infusion Therapies & Technologies | $981 | $994 | (1)% | (5)% |
| Advanced Surgery | 304 | 268 | 13% | 10% |
| &nbsp;&nbsp;Total Medical Product & Therapies net sales | $1285 | $1262 | 2% | (2)% |

---

1 &nbsp;&nbsp;&nbsp;&nbsp;Percent change in net sales at organic sales growth is a non-GAAP financial measure. See the section entitled "Non-GAAP Financial Measures" for additional information about our use of that measure.

Medical Product & Therapies segment net sales increased 2% in the first quarter of 2026, as compared to the prior year period.

Infusion Therapies & Technologies net sales decreased 1% in the first quarter of 2026, as compared to the prior year period. The decline in the first quarter was primarily due to lower Novum LVP pump sales as a result of the voluntary shipment and implementation hold. Sales volumes were further impacted by a strong prior year comparison in U.S. IV solutions businesses, during which we experienced strong sales due to a one-time distributor build following Hurricane Helene. Foreign exchange rates favorably impacted sales growth by 4% for the first quarter of 2026, as compared to the prior year period. As previously discussed in "Factors Affecting our Results of Operations", we elected to temporarily stop distributing and installing the Novum LVP in the U.S. and Canada, except in the case of medical necessity. As a result, we expect no meaningful sales of Novum LVP while these holds are in effect. Our Spectrum IQ large volume pump remains available as an alternative option for customers with Novum LVPs.

Advanced Surgery net sales increased 13% in the first quarter of 2026, as compared to the prior year period. Sales performance was primarily driven by growth in hemostats and sealants and was primarily attributable to increased sales volume globally. Foreign currency exchange rates favorably impacted sales growth by 3% for the first quarter of 2026, as compared to the prior year period.

------

**Healthcare Systems & Technologies**

Our Healthcare Systems & Technologies segment includes sales of our connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | Three Months Ended March 31, | Three Months Ended March 31, | Percent change | Percent change |
| (in millions) | 2026 | 2025 | At actual<br>rates | At organic sales growth <sup>1</sup> |
| Care & Connectivity Solutions | $435 | $427 | 2% | —% |
| Front Line Care | 270 | 277 | (3)% | (4)% |
| &nbsp;&nbsp;Total Healthcare Systems & Technologies net sales | $705 | $704 | —% | (2)% |

---

1 &nbsp;&nbsp;&nbsp;&nbsp;Percent change in net sales at organic sales growth is a non-GAAP financial measure. See the section entitled "Non-GAAP Financial Measures" for additional information about our use of that measure.

Healthcare Systems & Technologies segment net sales were flat in the first quarter of 2026, as compared to the prior year period.

Care & Connectivity Solutions net sales increased 2% in the first quarter of 2026, as compared to the prior year period. Sales performance was primarily driven by increased volume associated with increased capital spending by customers in the U.S. for patient support systems, offset by lower installations in our care communications portfolio. Foreign currency exchange rates favorably impacted sales growth by 2% for the first quarter of 2026, as compared to the prior year period.

Front Line Care net sales decreased 3% in the first quarter of 2026, as compared to the prior year period. The decline in the first quarter was primarily impacted by the timing of orders and the impact of planned global portfolio exits. Foreign currency exchange rates favorably impacted sales growth by 1% for the first quarter of 2026, as compared to the prior year period.

**Pharmaceuticals**

Our Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia and drug compounding.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | Three Months Ended March 31, | Three Months Ended March 31, | Percent change | Percent change |
| (in millions) | 2026 | 2025 | At actual<br>rates | At organic sales growth <sup>1</sup> |
| Injectables & Anesthesia | $301 | $335 | (10)% | (13)% |
| Drug Compounding | 320 | 246 | 30% | 20% |
| &nbsp;&nbsp;Total Pharmaceuticals net sales | $621 | $581 | 7% | 1% |

---

1 &nbsp;&nbsp;&nbsp;&nbsp;Percent change in net sales at organic growth rates is a non-GAAP financial measure. See the section entitled "Non-GAAP Financial Measures" for additional information about our use of that measure.

Pharmaceuticals segment net sales increased 7% in the first quarter of 2026, as compared to the prior year period.

Injectables & Anesthesia net sales decreased 10% in the first quarter of 2026, as compared to the prior year period. The sales decline in the first quarter was primarily driven by supply constraints in the U.S. and international markets and softness in certain premix products in our injectables portfolio and lower demand in anesthesia globally. Foreign exchange favorably impacted sales growth by 3% for the first quarter, as compared to the prior year period.

Drug Compounding net sales increased 30% in the first quarter of 2026, as compared to the prior year period. Sales performance was primarily driven by increased demand for our international pharmacy compounding offerings. Foreign currency exchange rates favorably impacted sales growth by 10% for the first quarter of 2026, as compared to the prior year period.

------

**Other** 

During the three months ended March 31, 2026 and 2025, we earned $90 million and $78 million, respectively, of revenues that were not attributable to our reportable segments. The increase in Other sales for the three months ended March 31, 2026 as compared to the prior year period reflects the impact of the Kidney Care MSA entered into upon the sale of our Kidney Care business in January 2025.

**COSTS AND EXPENSES**

**Special Items**

The following table provides a summary of our special items from continuing operations and the related impact by line item on our results for the three months ended March 31, 2026 and 2025.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | Three Months Ended March 31, | Three Months Ended March 31, | Three Months Ended March 31, | Three Months Ended March 31, |
| (in millions) | 2026 | 2026 | 2025 | 2025 |
| **Gross Margin** |  |  |  |  |
| Intangible asset amortization expense | $(95) |  | $(104) |  |
| Business optimization items<sup>1</sup> | (11) |  | (13) |  |
| European medical devices regulation<sup>2</sup> | (4) |  | (5) |  |
| Product-related items<sup>3</sup> | 12 |  | (6) |  |
| Business transformation<sup>4</sup> | (1) |  |  |  |
| Hurricane Helene costs<sup>5</sup> | (3) |  | (98) |  |
| Legal matters<sup>6</sup>  |  |  | (11) |  |
| Total Special Items | $(102) |  | $(237) |  |
| Impact on Gross Margin Ratio | (3.8) | pts | (9.0) | pts |
| **Selling, General and Administrative (SG&A) Expenses** |  |  |  |  |
| Intangible asset amortization expense | $51 |  | $51 |  |
| Business optimization items<sup>1</sup> | 42 |  | 30 |  |
| Acquisition and integration items<sup>7</sup> |  |  | 1 |  |
| Separation-related costs<sup>8</sup> | 11 |  | $13 |  |
| Business transformation<sup>4</sup> | 10 |  |  |  |
| Total Special Items | $114 |  | $95 |  |
| Impact on SG&A Ratio | 4.3 | pts | 3.6 | pts |
| **Research and Development (R&D) Expenses** |  |  |  |  |
| Business optimization items<sup>1</sup> | $15 |  | $2 |  |
| Total Special Items | $15 |  | $2 |  |
| Impact on R&D Ratio | 0.5 | pts | 0.0 pts | 0.0 pts |
| **Other (Income) Expense, net** |  |  |  |  |
| Investment impairments<sup>9</sup> | $5 |  | $9 |  |
| Acquisition and integration items<sup>7</sup> |  |  | 5 |  |
| Total Special Items | $5 |  | $14 |  |
| **Income Tax Expense** |  |  |  |  |
| Tax matters<sup>10</sup> | $26 |  | $(43) |  |
| Tax effects of special items<sup>11</sup> | (57) |  | (84) |  |
| Total Special Items | $(31) |  | $(127) |  |
| Impact on Effective Tax Rate | (201.6) | pts | 2215.9 | pts |

---

1Our results for the first quarter of 2026 and 2025 included business optimization charges of $68 million and $45 million, respectively. These restructuring and business optimization costs in 2026 and 2025 included costs primarily related to initiatives to reduce our cost structure following the sale of our former Kidney Care segment. Refer to Note 10 in Item 1 of this Quarterly Report on Form 10-Q for further information regarding these charges and related liabilities.

------

2Our results for the first quarter of 2026 and 2025 included $4 million and $5 million, respectively, of incremental costs to comply with the European Union's medical device regulations for previously registered products, which primarily consist of contractor costs and other direct third-party costs. We consider the adoption of these regulations to be a significant one-time regulatory change and believe that the costs of initial compliance for previously registered products over the implementation period are not indicative of our core operating results.

3Our results for the first quarter of 2026 included a benefit of $12 million related to a revised estimate of warranty and remediation activities from field corrective actions across our infusion pump category initially recorded in 2025. Our results for the first quarter of 2025 included charges of $6 million related to a revised estimate of warranty and remediation activities arising from a field corrective action on certain of our infusion pumps initially recorded in 2022.

4Our results in the first quarter of 2026 included charges of $11 million related to business transformation costs which include expenses incurred in connection with discrete, newly launched enterprise-wide initiatives to modernize and simplify systems, redesign operating models, and enhance process efficiency and digital capabilities. These costs are distinct from restructuring-related charges (which are included in footnote 1 above as Business Optimization items) and are excluded to provide investors with greater comparability of underlying operating performance.

5Our results in the first quarter of 2026 and 2025 included charges of $3 million and $98 million, respectively, related to damages caused by Hurricane Helene which consisted of remediation, air freight and other costs.

6Our results in the first quarter of 2025 included charges of $11 million related to matters involving alleged injury from environmental exposure.

7Our results for the first quarter of 2025 included $6 million of integration costs which primarily reflected the recognition of a non-cash impairment of properly, plant and equipment related to integration activities.

8Our results for the first quarter of 2026 and 2025 included $11 million and $13 million, respectively, of separation-related costs primarily reflecting costs of external advisors supporting our activities related to the sale of our former Kidney Care segment.

9Our results in the first quarter of 2026 and 2025 included $5 million and $9 million, respectively, related to losses from non-cash impairment write-downs of investments.

10Our results in the first quarter of 2026 included $26 million of income tax expense primarily related to an increase in interest related to uncertain tax positions and differences arising from the use of a forecasted effective tax rate to compute income tax expense during the quarter. Our results in the first quarter of 2025, included $43 million of income tax benefit driven by an entity classification election that we made for U.S. tax purposes, which resulted in a capital loss.

11This item reflects the income tax impact of the special items identified in this table. The tax effect of each special item is based on the jurisdiction in which the item was incurred and the tax laws in effect for each such jurisdiction.

**Gross Margin and Expense Ratios**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | Three Months Ended March 31, | Three Months Ended March 31, | Three Months Ended March 31, | Three Months Ended March 31, | Three Months Ended March 31, | Three Months Ended March 31, |
| | 2026 | % of net sales | 2025 | % of net sales | $ change | % change |
| Gross margin | $891 | 33.0% | $861 | 32.8% | $30 | 3.5% |
| SG&A | $728 | 27.0% | $703 | 26.8% | $25 | 3.6% |
| R&D | $139 | 5.1% | $140 | 5.3% | $(1) | (0.7)% |

---

<u>Gross Margin</u>

Our gross margin ratio was 33.0% and 32.8% for the three months ended March 31, 2026 and 2025, respectively. The special items identified earlier in this section had an unfavorable impact of approximately 3.8 and 9.0 percentage points on the gross margin ratio for the three months ended March 31, 2026 and 2025, respectively.

Excluding the impact of special items, the gross margin ratio decreased by 5.0 percentage points in the first quarter of 2026 compared to the prior year period. The lower gross margins were primarily driven by increased manufacturing and supply costs, tariffs and product mix.

<u>SG&A</u>

Our SG&A expenses ratio was 27.0% and 26.8% for the three months ended March 31, 2026 and 2025, respectively. The special items identified earlier in this section had an unfavorable impact of approximately 4.3 and 3.6 percentage points on the SG&A expenses ratio for the three months ended March 31, 2026 and 2025, respectively.

Excluding the impact of special items, the SG&A expenses ratio decreased by 0.5 percentage points in the first quarter of 2026 compared to the prior year period. The decrease primarily reflects lower headcount, partially offset by annual compensation increases.

<u>R&D</u>

Our R&D expenses ratio was 5.1% and 5.3% for each of the three months ended March 31, 2026 and 2025. The special items identified earlier in this section had an unfavorable impact of approximately 0.5 percentage points on the

------

R&D expenses ratio for the three months ended March 31, 2026 and no impact on the R&D expenses ratio for the three months ended March 31, 2025.

Excluding the impact of special items, the R&D expenses ratio decreased by 0.7 percentage points in the first quarter of 2026 compared to the prior year period primarily due to phasing of R&D spend which is expected to be consistent on a full year basis.

**Business Optimization Items**

In recent years, we have undertaken actions to transform our cost structure and enhance operational efficiency. These efforts have included restructuring the organization into verticalized segments, optimizing our manufacturing footprint, R&D operations, and supply chain network, employing disciplined cost management, and centralizing and streamlining certain support functions. The related costs of these actions consisted primarily of employee termination costs, implementation costs, contract termination costs, and asset impairments.

For the three months ended March 31, 2026, $58 million of the restructuring charges, consisting of employee termination costs, were related to initiatives to reduce our cost structure following the sale of our Kidney Care segment.

We currently expect to incur additional pre-tax costs, primarily related to the implementation of business optimization programs, of approximately $2 million through the completion of certain initiatives that are currently underway. We continue to pursue cost savings initiatives, including those intended to mitigate a portion of the dis-synergies that arose as a result of the sale of our Kidney Care business, and to the extent further cost savings opportunities are identified, we would incur additional restructuring charges and costs to implement business optimization programs in future periods. Refer to Note 10 in Item 1 of this Quarterly Report on Form 10-Q for additional information regarding our business optimization programs.

**Other Operating Income, Net**

Other operating income, net was $42 million and $40 million in the first quarter of 2026 and 2025, respectively, and these amounts were primarily related to the income recognized under the Kidney Care TSA entered into upon the sale of the Kidney Care business in January 2025.

**Interest Expense, Net**

Interest expense, net was $66 million and $64 million in the first quarter of 2026 and 2025, respectively. The slight increase in 2026 was driven by higher interest expense on senior notes issued in the fourth quarter of 2025 partially offset by debt repayments in the first three months of 2025.

**Other (Income) Expense, net**

Other (income) expense, net was expense of $6 and income of $3 million in the first quarter of 2026 and 2025, respectively. In the current year period, the decrease in other (income) expense, net was primarily driven pension and other postretirement benefits and foreign exchange losses.

**Income Taxes**

Our effective income tax rate can differ from the 21% U.S. federal statutory rate due to a number of factors, including foreign rate differences, tax incentives, non-deductible expenses, non-taxable income, increases or decreases in valuation allowances, increases or decreases in liabilities for uncertain tax positions, and excess tax benefits or shortfalls on stock compensation awards.

For the three months ended March 31, 2026, the difference between our effective income tax rate and the U.S. federal statutory rate was primarily driven by our near break-even pre-tax results and increases to our valuation allowance on U.S. deferred tax assets. The quarter also reflects income tax recorded related to tax shortfalls on stock compensation awards.

For the three months ended March 31, 2025, the difference between our effective income tax rate and the U.S. federal statutory rate was primarily driven by our near break-even pre-tax income and a tax benefit driven by an entity classification election that we made for U.S. tax purposes, which resulted in a capital loss.

------

We are currently under examination by the Internal Revenue Service (IRS) for transfer pricing matters related to transactions with our manufacturing operations in Costa Rica and Puerto Rico for the 2019 and 2020 tax years. During the quarter, we received a Notice of Proposed Adjustment (NOPA) from the IRS covering the 2019 and 2020 tax years that is consistent with our existing and previously disclosed uncertain tax position reserves. We did not record further reserves in connection with the NOPA, other than interest that may be owed upon conclusion of the audit. While we believe that our transfer pricing positions are well documented and properly supported, and adequate amounts have been reserved to account for any adjustments that may ultimately result from this examination, the matter remains open for resolution. Additionally, if the IRS were to assert we owe additional taxes and prevails in this assertion, such outcome could have a material impact on our financial position, results of operations, and cash flows.

During 2025, because of a cumulative history of operating losses in the U.S., we recorded a valuation allowance against our U.S. deferred tax assets, including certain federal and state tax attributes such as foreign tax credits. Although we expect to remain in a U.S. valuation allowance position for at least the next 12 months, we also anticipate future changes in the amount of the valuation including during 2026, which could be material, due to operational activity and movement in our routine deferred tax assets and liabilities.

The Organization of Economic Co-operation and Development (OECD) reached agreement among over 140 countries to implement a minimum 15% tax rate on certain multinational enterprises, commonly referred to as Pillar Two. During the quarter, the OECD published administrative guidance proposing a Side-by-Side safe harbor, which may reduce the impact of Pillar Two for U.S. headquartered multinational corporations. We will monitor the implementation of the Side-by-Side safe harbor by individual jurisdictions, however we do not expect the impact of Pillar Two to be material in any case.

**Discontinued Operations** 

On January 31, 2025, we completed the sale of our Kidney Care business and its results have been presented as discontinued operations for the three months ended March 31, 2026 and 2025. Income (loss) from discontinued operations, net of tax was $2 million in the first quarter of 2026, compared to $62 million in the first quarter of 2025.The decrease in the current year period was primarily driven by the gain on the sale of our Kidney Care business for the three months ended March 31, 2025. Refer to Note 2 within Item 1 for additional information.

------

**SEGMENT OPERATING INCOME**

The following is a summary of our operating income for our reportable segments.

---

| | | |
|:---|:---|:---|
| | Three Months Ended March 31, | Three Months Ended March 31, |
| (in millions) | 2026 | 2025 |
| &nbsp;&nbsp;Medical Products & Therapies | $186 | $244 |
| &nbsp;&nbsp;*% of Segment Net Sales* | *14.5 %* | *19.3 %* |
| &nbsp;&nbsp;Healthcare Systems & Technologies | 66 | 93 |
| &nbsp;&nbsp;*% of Segment Net Sales* | *9.4 %* | *13.2 %* |
| &nbsp;&nbsp;Pharmaceuticals | 46 | 63 |
| &nbsp;&nbsp;*% of Segment Net Sales* | *7.4 %* | *10.8 %* |
| Total reportable segment operating income | 298 | 400 |
| &nbsp;&nbsp;Other | 11 | 9 |
| &nbsp;&nbsp;Unallocated corporate costs | (12) | (17) |
| &nbsp;&nbsp;Intangible asset amortization expense | (146) | (155) |
| &nbsp;&nbsp;Legal matters |  | (11) |
| &nbsp;&nbsp;Business optimization items | (68) | (45) |
| &nbsp;&nbsp;Acquisition and integration items |  | (1) |
| &nbsp;&nbsp;Separation-related costs | (11) | (13) |
| &nbsp;&nbsp;European Medical Devices Regulation | (4) | (5) |
| &nbsp;&nbsp;Product-related items | 12 | (6) |
| &nbsp;&nbsp;Business transformation | (11) |  |
| &nbsp;&nbsp;Hurricane Helene Costs | (3) | (98) |
| Total operating income | 66 | 58 |
| &nbsp;&nbsp;Interest expense, net | 66 | 64 |
| &nbsp;&nbsp;Other (income) expense, net | 6 | (3) |
| Income from continuing operations before income taxes | $(6) | $(3) |

---

**Medical Products & Therapies**

Segment operating income was $186 million and $244 million in the first quarter of 2026 and 2025, respectively. The decrease in segment operating income in the first quarter compared to the prior year period was primarily driven by increased manufacturing and supply costs, tariffs and lower sales volumes.

**Healthcare Systems & Technologies**

Segment operating income was $66 million and $93 million in the first quarter of 2026 and 2025, respectively. Segment operating income decreased in the first quarter compared to the prior year period primarily due to increased manufacturing and supply costs, tariffs and lower sales volumes.

**Pharmaceuticals**

Segment operating income was $46 million and $63 million in the first quarter of 2026 and 2025, respectively. Segment operating income decreased in the first quarter compared to the prior year period primarily due to increased manufacturing and supply costs, price impacts resulting from increased competition and supply constraints which impacted select higher margin products.

**Other**

Other operating income, which represents operating income not attributable to our reportable segments, was $11 million and $9 million in the first quarter of 2026 and 2025, respectively. Other operating income increased in the first quarter compared to the prior year period primarily due to a longer period of income recognition in the current quarter.

------

In the prior year period, income from revenues earned under the Kidney Care MSA was recognized following the closing of the sale of the Kidney Care business on January 31, 2025, whereas income from revenues earned under the Kidney Care MSA was recognized for the full period in the current year.

<u>Unallocated Corporate Costs</u>

Under our operating model, most global functional support costs, overhead costs and other shared costs that benefit our segments are allocated to those segments. Corporate costs that are not allocated to our segments, as well as any differences between actual corporate costs and the amounts allocated to our segments, are presented as unallocated corporate costs. Additionally, intangible asset amortization and other special items are not allocated to our segments.

**<u>LIQUIDITY AND CAPITAL RESOURCES</u>**

The following table is a summary of the statement of cash flows for the three-month periods ended March 31, 2026 and 2025.

---

| | | |
|:---|:---|:---|
| | Three Months Ended March 31, | Three Months Ended March 31, |
| (in millions) | 2026 | 2025 |
| Cash flows from (used in) operations - continuing operations | $213 | $(99) |
| Cash flows from (used in) investing activities - continuing operations | (133) | $(124) |
| Cash flows from (used in) financing activities | (11) | $(3226) |

---

**Cash Flows from Operations - Continuing Operations** 

For the three months ended March 31, 2026, operating cash flows from continuing operations were $213 million. For the three months ended March 31, 2025, operating cash flows used in continuing operations were $99 million. Operating cash flows from continuing operations in the current year period were favorably impacted by improved collections on accounts receivable and the extension of vendor payment terms.

**Cash Flows from Investing Activities - Continuing Operations**

For the three months ended March 31, 2026, cash used in investing activities from continuing operations primarily included capital expenditures of $137 million. For the three months ended March 31, 2025, cash used in investing activities from continuing operations primarily included capital expenditures of $122 million.

**Cash Flows from Financing Activities** 

For the three months ended March 31, 2026, cash used in financing activities primarily included payments for tax shares withheld for stock issued under employee benefit plans. For the three months ended March 31, 2025, cash used in financing activities included debt repayments of $2.83 billion, a decrease in commercial paper borrowings of $300 million, and dividend payments of $87 million, partially offset by proceeds from stock issued under employee benefit plans of $10 million.

As authorized by our Board of Directors, we repurchase our stock depending upon our cash flows, net debt levels and market conditions. In July 2012, our Board of Directors authorized a share repurchase program and the related authorization was subsequently increased a number of times. We did not repurchase any shares under this authority in the first three months of 2026. We had $1.30 billion remaining available under this authorization as of March 31, 2026.

**Credit Facilities, Commercial Paper Program and Access to Capital and Credit Ratings**

<u>Credit Facilities and Commercial Paper Program</u>

As of March 31, 2026, we had a multicurrency revolving credit facility, as described below.

Our Multicurrency Revolver has a maximum capacity of $2.20 billion and matures in 2030. Borrowings under the Multicurrency Revolver in U.S. dollars bear interest on the principal amount outstanding at either Term SOFR plus an applicable margin or a "base rate" plus an applicable margin. The Multicurrency Revolver contains various covenants, including a maximum net leverage ratio. Borrowings in Euros are subject to a sublimit of $300 million. We may, at our option, seek to increase the aggregate commitment under the Multicurrency Revolver by up to $1.10 billion, which

------

would result in a maximum aggregate commitment of up to $3.30 billion. There were no borrowings outstanding under the Multicurrency Revolver as of March 31, 2026 or December 31, 2025. Our commercial paper borrowing arrangements require us to maintain undrawn borrowing capacity under the Multicurrency Revolver for an amount at least equal to our outstanding commercial paper borrowings.

As of March 31, 2026, we were in compliance with the financial covenant in the Multicurrency Revolver. Based on our covenant calculations as of March 31, 2026, we had capacity to draw $1.62 billion under the Multicurrency Revolver. The non-performance of any financial institution supporting the Multicurrency Revolver would reduce the maximum capacity thereunder by such institution's respective commitment.

<u>Access to Capital and Credit Ratings</u>

We intend to fund short-term and long-term obligations as they mature through cash on hand, future cash flows from operations, or by issuing additional debt, which could include commercial paper. We had $2.02 billion of cash and cash equivalents as of March 31, 2026, with adequate cash available to meet operating requirements in each jurisdiction in which we operate. We invest our excess cash in money market and other funds and diversify the concentration of cash among different financial institutions. As of March 31, 2026, we had approximately $9.46 billion of long-term debt and finance lease obligations, including current maturities and short-term debt. Subject to market conditions, we regularly evaluate opportunities with respect to our capital structure (including with respect to the potential refinancing of our outstanding indebtedness).

Our ability to generate cash flows from operations, issue debt, including commercial paper, or enter into other financing arrangements on acceptable terms could be adversely affected if there is a material decline in the demand for our products or in the solvency of our customers or suppliers, deterioration in our credit ratings (as discussed below), or other significantly unfavorable changes in conditions (including if our key financial ratios do not show sustained improvement). However, we believe we have sufficient financial flexibility to issue additional debt, enter into other financing arrangements, and attract long-term capital on acceptable terms to support our growth objectives and reduce our debt levels as we take actions consistent with our capital allocation priorities.

Our credit ratings are subject to ongoing review by the rating agencies, and they consider a number of factors, including our financial strength, performance, prospects and operations as well as factors not under our control. The rating agencies could make adjustments to our ratings at any time, and they provide no assurances that they will maintain our ratings at current level. During the first quarter of 2026, Standard & Poor's and Moody's Ratings revised our outlook from Stable to Negative. There have been no other changes to our credit ratings that we disclosed in our 2025 Annual Report.

**<u>CRITICAL ACCOUNTING POLICIES</u>**

The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses. A summary of our significant accounting policies is included in Note 1 to our consolidated financial statements in our 2025 Annual Report. Certain of our accounting policies are considered critical, as these policies are the most important to the depiction of our financial statements and require significant, difficult or complex judgments by us, often employing the use of estimates about the effects of matters that are inherently uncertain. Such policies are summarized in the Management's Discussion and Analysis of Financial Condition and Results of Operations section in our 2025 Annual Report.

**Impairment of Goodwill and Other Long-Lived Assets**

<u>Front Line Care Reporting Unit</u>

In connection with our November 1, 2025 annual goodwill impairment tests, we recorded a goodwill impairment

related to our Front Line Care reporting unit within our Healthcare Systems & Technologies segment to reduce the carrying value of the reporting unit to its fair value. While no triggering events were identified during the three months ended March 31, 2026, we are continuing to closely monitor the performance of this reporting unit (including in light of evolving global macroeconomic conditions and capital spending patterns), and if there is a significant adverse change in our outlook for this business in the future, a goodwill impairment could arise at that time. As of March 31, 2026, the carrying amount of goodwill for our Front Line Care reporting unit was $1.51 billion.

------

<u>Welch Allyn Trade Name</u>

In connection with our annual trade name impairment assessment in the fourth quarter of 2025, we recognized an impairment charge to reduce the carrying amount of the Welch Allyn trade name within our Healthcare Systems & Technologies segment, an indefinite-lived intangible asset, to its estimated fair value. While no triggering events were identified during the three months ended March 31, 2026, we are continuing to closely monitor the performance of this intangible asset (including in light of evolving global macroeconomic conditions and capital spending patterns), and if there is a significant adverse change in our outlook for this intangible asset in the future, an intangible asset impairment could arise at that time. As of March 31, 2026, the carrying amount of the Welch Allyn Trade Name was $390 million.

There have been no significant changes in the application of our critical accounting policies during the first three months of 2026.

**<u>RECENT ACCOUNTING PRONOUNCEMENTS</u>**

*Recently issued accounting standards not yet adopted*

In November 2024, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires disaggregated disclosure of certain expenses on an interim and annual basis in the notes to the financial statements. This standard is effective for annual consolidated financial statements for the year ending December 31, 2027 and for interim periods beginning in 2028. We are currently evaluating the impact of this new standard on our consolidated financial statements.

**<u>LEGAL CONTINGENCIES</u>**

Refer to Note 6 within Item 1 for a discussion of our legal contingencies. Upon resolution of any of these uncertainties, we may incur charges in excess of presently established liabilities. While our liability in connection with certain claims cannot be estimated with any certainty, and although the resolution in any reporting period of one or more of these matters could have a significant impact on our results of operations and cash flows for that period, the outcome of these legal proceedings is not currently expected to have a material adverse effect on our consolidated financial position. While we believe that we have valid defenses in these matters, litigation is inherently uncertain, excessive verdicts do occur, and we may in the future incur material judgments or enter into material settlements of claims.

**<u>CERTAIN REGULATORY MATTERS</u>**

In July 2017, immediately prior to the closing of our acquisition of Claris Injectables Limited (Claris), FDA commenced an inspection of the Claris' facilities in Ahmedabad, India. FDA completed the inspection and subsequently issued a Warning Letter based on observations identified in the 2017 inspection¹. FDA completed a re-inspection of the facilities in May 2022, which was subsequently classified as Voluntary Action Indicated (VAI). FDA performed an additional inspection of the facilities in January 2023. In April 2023, the site received an Official Action Indicated, or "OAI", classification following FDA's January 2023 inspection. In July 2023, FDA issued a Warning Letter to the site based on the observations from the agency's January 2023 inspection (2023 Warning Letter)<sup>2</sup>. In June 2025, FDA performed another re-inspection of the site. On October 31, 2025, FDA classified the June 2025 inspection as VAI, indicating that the site is in acceptable compliance with FDA's current Good Manufacturing Practice requirements. Based on the VAI reclassification, Baxter expects that the 2023 Warning Letter will be closed and no additional Warning Letters on the facilities will remain outstanding.

<sup>1</sup> Available online at https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm613538.htm

<sup>2</sup> Available online at https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/baxter-healthcare-corporation-654136-07252023

**<u>FORWARD-LOOKING INFORMATION</u>** 

Certain statements contained in this quarterly report on Form 10-Q may constitute "forward-looking statements," as defined in the Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. These statements by their nature address matters that are

------

uncertain to different degrees. Use of the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "seeks," "intends," "evaluates," "pursues," "anticipates," "continues," "designs," "impacts," "affects," "forecasts," "target," "outlook," "initiative," "objective," "designed," "priorities," "goal," or the negative of those words or other similar expressions may identify forward-looking statements, although not all forward-looking statements contain such words.

These forward-looking statements are based on certain assumptions and analyses made in light of our experience and perception of historical trends, current conditions, and expected future developments as well as other factors that we believe are appropriate in the circumstances. While these statements represent our judgment on what the future may hold, and we believe these judgments are reasonable, these statements are not guarantees of any events or financial results. Whether actual future results and developments will conform to expectations and predictions is subject to a number of risks and uncertainties, including the following factors, many of which are beyond our control:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We are exposed to risks as a result of our strategic actions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We may not achieve the anticipated benefits of our significant transactions, including the sale of our Kidney Care business and our acquisition of Hillrom;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our significant indebtedness requires us to use a substantial amount of our cash flow for debt service and constrains our ability to pursue growth strategies and advance our R&D capabilities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• There is substantial competition in the product markets in which we operate and the risk of declining demand and pricing pressures could adversely affect our business, results of operations, financial condition and cash flows;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We may be unable to successfully introduce or monetize new and existing products or services or keep pace with changing consumer preferences and needs or advances in technology;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We may not achieve our financial goals;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We have experienced disruptions in our supply chain;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Global economic conditions, including inflation, have adversely affected, and could continue to adversely affect, our operations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We may not be successful in achieving expected operating efficiencies and sustaining or improving operating expense reductions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Continued consolidation in the health care industry or additional governmental controls exerted over pricing and access in key markets could lead to increased demands for price concessions or limit or eliminate our ability to sell to certain of our significant market segments;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our operating results and financial condition have fluctuated and may in the future continue to fluctuate;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Management transition creates uncertainties, and we may experience difficulties in managing such transitions, including attracting and retaining key employees;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Changes in foreign currency exchange rates and interest rates have had, and may in the future have, an adverse effect on our results of operations, financial condition, cash flows, and liquidity;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We are subject to risks associated with doing business globally, including changes in tariffs and trade policies and treaties (including with respect to the validity of previously issued tariffs and the availability of any related refunds) as well as the ongoing Iran conflict and other geopolitical events;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Future material impairments in the value of our goodwill, intangible assets, and other long-lived assets would negatively affect our operating results;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Segments of our business are significantly dependent on major contracts with group purchasing organizations, integrated delivery networks, and certain other distributors and purchasers;

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We may be unable to obtain sufficient components or raw materials on a timely basis or for a cost-effective price;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We may experience manufacturing, sterilization, supply, or distribution difficulties;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We have experienced and may continue to experience issues with quality management or product quality, including with respect to Novum LVP;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We may experience breaches and breakdowns affecting our information technology systems or protected information, including from obsolescence, cyber security breaches and data leakage;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We are exposed to risks associated with incorporating artificial intelligence (AI), machine learning and other emerging technologies into our products, services and operations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• A portion of our workforce is unionized, and we could face labor disruptions that would interfere with our operations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The effects of climate change, including legal, regulatory, or market measures related to climate change and other sustainability topics, could adversely affect our business, results of operations, financial condition, and cash flows;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our commitments, goals, activities, and disclosures related to sustainability and corporate responsibility matters, and the perception of our activities in these areas, may fail to satisfy the differing expectations of key stakeholders on these matters;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We are subject to laws and regulations globally, and our failure to comply with rapidly changing and increasingly divergent expectations of regulators in different jurisdictions could adversely impact the company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• If reimbursement or other payment for our current or future products is reduced or modified in the U.S. or in foreign countries, or there are changes to policies with respect to pricing, taxation, or rebates, our business could suffer;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Increasing regulatory focus on, and expanding laws relating to, privacy, AI, and cybersecurity could impact our business and expose us to increased liability;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We are party to a number of pending lawsuits and other disputes which may adversely impact us;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We could be subject to fines or damages and possible exclusion from participation in federal or state healthcare programs if we fail to comply with the laws and regulations applicable to our business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• If we are unable to protect or enforce our patents or other proprietary rights, or if we become subject to claims or litigation alleging infringement of the patents or other proprietary rights of others, our competitiveness and business prospects may be materially damaged;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Changes in tax laws or exposure to additional income tax liabilities may have a negative impact on our operating results;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our Amended and Restated Bylaws could limit our stockholders' ability to choose their preferred judicial forum for disputes with us or our directors, officers, or employees;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We recently decreased our quarterly dividend to $0.01 per share and cannot guarantee that we will increase the amount of dividends we pay, or that we will not cease paying dividends;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our common stock price has fluctuated significantly and may continue to do so; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• other factors discussed elsewhere in this report and other filings with the SEC, including those factors described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025, all of which are available on our website.

------

Actual results may differ materially from those projected in the forward-looking statements, which are more fully discussed in Item 1A. Risk Factors and Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations and elsewhere in our 2025 Annual Report. These forward-looking statements are not exclusive and are in addition to other factors discussed elsewhere in our 2025 Annual Report. Further, other unknown or unpredictable factors could also have material adverse effects on future results. Any forward-looking statement in this Quarterly Report on Form 10-Q speaks only as of the date on which it is made. Except as required by law, we assume no obligation, and expressly disclaim any obligation, to update or revise any forward-looking statements, whether as a result of new information or future events.

------

Item 3.&nbsp;&nbsp;&nbsp;&nbsp;Quantitative and Qualitative Disclosures About Market Risk

**Currency Risk**

We are primarily exposed to foreign exchange risk with respect to revenues generated outside of the United States denominated in the Euro, Australian Dollar, British Pound, and Canadian Dollar. We manage our foreign currency exposures on a consolidated basis, which allows us to net exposures and take advantage of any natural offsets. In addition, we use derivative and nonderivative financial instruments to further reduce the net exposure to foreign exchange. Gains and losses on the hedging instruments offset losses and gains on the hedged transactions and reduce the earnings and stockholders' equity volatility relating to foreign exchange. However, we don't hedge our entire foreign exchange exposure and are still subject to earnings and stockholders' equity volatility relating to foreign exchange risk. Financial market and currency volatility may limit our ability to cost-effectively hedge these exposures.

We primarily use forward contracts to hedge the foreign exchange risk to earnings relating to forecasted transactions and recognized assets and liabilities denominated in foreign currencies. We also enter into derivative instruments to hedge foreign exchange risk on certain intra-company and third-party receivables and payables and debt denominated in foreign currencies.

As part of our risk-management program, we perform sensitivity analyses to assess potential changes in the fair value of our foreign exchange instruments relating to hypothetical and reasonably possible near-term movements in foreign exchange rates.

A sensitivity analysis of changes in the fair value of foreign exchange contracts outstanding as of March 31, 2026, while not predictive in nature, indicated that if the U.S. Dollar uniformly weakened by 10% against all currencies, the net pre-tax liability balance of $2 million with respect to those contracts would change by $2 million.

The sensitivity analysis model recalculates the fair value of the foreign exchange contracts outstanding as of March 31, 2026 by replacing the actual exchange rates as of March 31, 2026 with exchange rates that are 10% weaker compared to the actual exchange rates for each applicable currency. All other factors are held constant. These sensitivity analyses disregard the possibility that currency exchange rates can move in opposite directions and that gains from one currency may or may not be offset by losses from another currency. The analyses also disregard the offsetting change in value of the underlying hedged transactions and balances.

In February 2022, the three-year cumulative inflation rate in Turkey exceeded 100 percent. As a result, on April 1, 2022, we began reporting the results of our subsidiary in that jurisdiction using highly inflationary accounting, which requires that the functional currency of the entity be changed to the reporting currency of its parent. As of March 31, 2026, our subsidiary in Turkey had net monetary assets of $37 million.

**Interest Rate and Other Risks**

Refer to the caption "Interest Rate and Other Risks" in the "Financial Instrument Market Risk" section of the 2025 Annual Report. There were no significant changes during the quarter ended March 31, 2026.

------

Item 4.&nbsp;&nbsp;&nbsp;&nbsp;Controls and Procedures

<u>Evaluation of Disclosure Controls and Procedures</u>

Our management, with the participation of our Chief Executive Officer and our Interim Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act), as of March 31, 2026. Based on that evaluation, our Chief Executive Officer and our Interim Chief Financial Officer concluded that our disclosure controls and procedures were effective as of March 31, 2026.

<u>Chan</u>g<u>es in Internal Control over Financial Reporting</u>

There have been no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended March 31, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

------

PART II. OTHER INFORMATION

Item 1.&nbsp;&nbsp;&nbsp;&nbsp;Legal Proceedings

The information in Part I, Item 1, Note 6 is incorporated herein by reference.

Item 1A. Risk Factors

We do not believe that there have been any material changes to the risk factors previously disclosed in our 2025 Annual Report.

Item 2.&nbsp;&nbsp;&nbsp;&nbsp;Unregistered Sales of Equity Securities and Use of Proceeds

In July 2012, the Board of Directors authorized a share repurchase program and the related authorization was subsequently increased a number of times. During the first quarter of 2026, we did not repurchase any shares under this authority. We had $1.30 billion remaining under this program as of March 31, 2026. This program does not have an expiration date.

Item 5. Other Information

Certain of our officers have made elections to participate in, and are participating in, our employee stock purchase plan, and certain of our officers and directors have made, and may from time to time make, elections to have shares withheld to cover withholding taxes or pay the exercise price of options, which may constitute non-Rule 10b5-1 trading arrangements (as defined in Item 408(c) of Regulation S-K). Further, our officers are eligible to participate in Baxter's U.S. tax-qualified Section 401(k) plan (401(k) Plan). The 401(k) Plan permits both employer and employee contributions to be invested through a self-directed "brokerage window", which is subject to Rule 10b5-1(c)(1).

------

Item 6.&nbsp;&nbsp;&nbsp;&nbsp;Exhibits

Exhibit Index:

---

| | |
|:---|:---|
| Exhibit<br>Number | Description |
| 31.1\* | <u>[Certification of Chief Executive Officer Pursuant to Rules 13a-14 (a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended.](bax-20260331xex311.htm)</u> |
| 31.2\* | <u>[Certification of Interim Chief Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended.](bax-20260331xex312.htm)</u> |
| 32.1\*\* | <u>[Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](bax-20260331ex321.htm)</u> |
| 32.2\*\* | <u>[Certification of Interim Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](bax-20260331xex322.htm)</u> |
| 101.INS\* | XBRL Instance Document |
| 101.SCH\* | XBRL Taxonomy Extension Schema Document |
| 101.CAL\* | XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.LAB\* | XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE\* | XBRL Taxonomy Extension Presentation Linkbase Document |
| 101.DEF\* | XBRL Taxonomy Extension Definition Linkbase Document |
| 104\* | Cover Page Interactive Data File (formatted as Inline XBRL and contained within the Inline XBRL Instance Document in Exhibit 101) |

---

_____________________________________

\*&nbsp;&nbsp;&nbsp;&nbsp;Filed herewith.

\*\*&nbsp;&nbsp;&nbsp;&nbsp;Furnished herewith. This exhibit shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that Section. Such exhibit shall not be deemed incorporated into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934.

------

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | | BAXTER INTERNATIONAL INC. |
| | | (Registrant) |
| &nbsp;&nbsp;&nbsp;Date: April 30, 2026 |  |  |
|  | By: | /s/ Anita A. Zielinski |
|  |  | Anita A. Zielinski<br>Interim Chief Financial Officer and Senior Vice President, Chief Accounting Officer and Controller <br>(duly authorized officer and principal financial and accounting officer) |

---

## Exhibit 31.1

**EXHIBIT 31.1**

**Certification of Chief Executive Officer**

**Pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as Amended**

I, Andrew P. Hider, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.I have reviewed this Quarterly Report on Form 10-Q of Baxter International Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| |
|:---|
| /s/ Andrew P. Hider |
| Andrew P. Hider |
| President and Chief Executive Officer |
| Date: April 30, 2026 |

---

## Exhibit 31.2

**EXHIBIT 31.2**

**Certification of Chief Financial Officer**

**Pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as Amended**

I, Anita A. Zielinski, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.I have reviewed this Quarterly Report on Form 10-Q of Baxter International Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| |
|:---|
| /s/ Anita A. Zielinski |
| Anita A. Zielinski |
| Interim Chief Financial Officer and Senior Vice President,<br>Chief Accounting Officer and Controller |
| Date: April 30, 2026 |

---

## Exhibit 32.1

**EXHIBIT 32.1**

**Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

Andrew P. Hider, as President and Chief Executive Officer of Baxter International Inc. (the "Company"), certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)the Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026 as filed with the Securities and Exchange Commission on the date hereof (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| |
|:---|
| /s/ Andrew P. Hider |
| Andrew P. Hider |
| President and Chief Executive Officer |
| Date: April 30, 2026 |

---

## Exhibit 32.2

**EXHIBIT 32.2**

**Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

Anita A. Zielinski, as Interim Chief Financial Officer of Baxter International Inc. (the "Company"), certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)the Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026 as filed with the Securities and Exchange Commission on the date hereof (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| |
|:---|
| /s/ Anita A. Zielinski |
| Anita A. Zielinski |
| Interim Chief Financial Officer and Senior Vice President,<br>Chief Accounting Officer and Controller |
| Date: April 30, 2026 |

---

<br>